| Year | Citation | Score | |||
|---|---|---|---|---|---|
| 2022 | Besançon M, Gris T, Joncas FH, Picard V, Bergeron A, Fradet Y, Toren P. Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment. European Urology Open Science. 43: 35-44. PMID 36246841 DOI: 10.1016/j.euros.2022.06.007 | 0.301 | |||
| 2021 | Plante A, Dallaire F, Grosset AA, Nguyen T, Birlea M, Wong J, Daoust F, Roy N, Kougioumoutzakis A, Azzi F, Aubertin K, Kadoury S, Latour M, Albadine R, Prendeville S, ... ... Fradet Y, et al. Dimensional reduction based on peak fitting of Raman micro spectroscopy data improves detection of prostate cancer in tissue specimens. Journal of Biomedical Optics. 26. PMID 34743445 DOI: 10.1117/1.JBO.26.11.116501 | 0.333 | |||
| 2020 | Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bögemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, ... Fradet Y, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. The Lancet. Oncology. PMID 32971005 DOI: 10.1016/S1470-2045(20)30541-6 | 0.327 | |||
| 2020 | Grosset AA, Dallaire F, Nguyen T, Birlea M, Wong J, Daoust F, Roy N, Kougioumoutzakis A, Azzi F, Aubertin K, Kadoury S, Latour M, Albadine R, Prendeville S, Boutros P, ... ... Fradet Y, et al. Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case-control study with multicohort validation. Plos Medicine. 17: e1003281. PMID 32797086 DOI: 10.1371/Journal.Pmed.1003281 | 0.423 | |||
| 2020 | Toren P, Brisson H, Simonyan D, Hovington H, Lacombe L, Bergeron A, Fradet Y. Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival. World Journal of Urology. PMID 32676741 DOI: 10.1007/S00345-020-03358-X | 0.336 | |||
| 2020 | Lévesque E, Labriet A, Hovington H, Allain ÉP, Melo-Garcia L, Rouleau M, Brisson H, Turcotte V, Caron P, Villeneuve L, Leclercq M, Droit A, Audet-Walsh E, Simonyan D, Fradet Y, et al. Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression. British Journal of Cancer. PMID 32047296 DOI: 10.1038/S41416-020-0749-2 | 0.454 | |||
| 2020 | Leong DP, Fradet V, Shayegan B, Duceppe E, Siemens R, Niazi T, Klotz L, Brown I, Chin J, Lavallee L, Mousavi N, Luke P, Lukka H, Gopaul D, Violette P, ... ... Fradet Y, et al. Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study. The Journal of Urology. 101097JU000000000000. PMID 31899651 DOI: 10.1097/Ju.0000000000000714 | 0.441 | |||
| 2020 | Pinthus JH, Shayegan B, Klotz L, Siemens DR, Luke PP, Niazi T, Fradet V, Fradet Y, Duceppe E, Lavallee L, Mousavi N, Hamilton RJ, Brown I, Chin J, Gopaul D, et al. The prevalence of cardiovascular disease and its risk factors among prostate cancer patients treated with and without androgen deprivation. Journal of Clinical Oncology. 38: 364-364. DOI: 10.1200/Jco.2020.38.6_Suppl.364 | 0.409 | |||
| 2020 | Pinthus* J, Shayegan B, Siemens R, Klotz L, Luke P, Niazi T, Fradet V, Fradet Y, Duceppe E, Lavallee L, Mousavi N, Hamilton R, Brown I, Chin J, Gopaul D, et al. PD13-10 THE PREVALENCE OF CARDIOVASCULAR DISEASE AND ITS RISK FACTORS AMONG PROSTATE CANCER PATIENTS TREATED WITH AND WITHOUT ANDROGEN DEPRIVATION The Journal of Urology. 203: e270. DOI: 10.1097/Ju.0000000000000847.010 | 0.393 | |||
| 2019 | McMartin C, Lacombe L, Fradet V, Fradet Y, Lodde M, Toren P. Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive? Clinical Genitourinary Cancer. PMID 31594737 DOI: 10.1016/J.Clgc.2019.07.016 | 0.356 | |||
| 2019 | Houlahan KE, Shiah YJ, Gusev A, Yuan J, Ahmed M, Shetty A, Ramanand SG, Yao CQ, Bell C, O'Connor E, Huang V, Fraser M, Heisler LE, Livingstone J, Yamaguchi TN, ... ... Fradet Y, et al. Genome-wide germline correlates of the epigenetic landscape of prostate cancer. Nature Medicine. PMID 31591588 DOI: 10.1038/S41591-019-0579-Z | 0.377 | |||
| 2019 | Joncas FH, Lucien F, Rouleau M, Morin F, Leong HS, Pouliot F, Fradet Y, Gilbert C, Toren P. Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients. The Prostate. PMID 31475741 DOI: 10.1002/Pros.23901 | 0.411 | |||
| 2019 | Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of > 2 years of follow-up. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 31050707 DOI: 10.1093/Annonc/Mdz127 | 0.372 | |||
| 2019 | Trinh VQ, Benzerdjeb N, Chagnon-Monarque S, Dionne N, Delouya G, Kougioumoutzakis A, Sirois J, Albadine R, Latour M, Mes-Masson AM, Hovington H, Bergeron A, Zorn KC, Fradet Y, Saad F, et al. Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate. Radiation Oncology (London, England). 14: 60. PMID 31018850 DOI: 10.1186/S13014-019-1267-3 | 0.434 | |||
| 2019 | Haider M, Ladurner C, Mayr R, Tandogdu Z, Fritsche HM, Fradet V, Comploj E, Pycha A, Lemire F, Lacombe L, Fradet Y, Toren P, Lodde M. Use and duration of antibiotic prophylaxis and the rate of urinary tract infection after radical cystectomy for bladder cancer: Results of a multicentric series. Urologic Oncology. PMID 30871997 DOI: 10.1016/J.Urolonc.2019.01.017 | 0.331 | |||
| 2019 | Kulkarni GS, Black PC, Sridhar SS, Kapoor A, Zlotta AR, Shayegan B, Rendon R, Chung P, Van Der Kwast T, Alimohamed N, Fradet Y, Kassouf W. Canadian Urological Association guideline: Muscle-invasive bladder cancer. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 30763236 DOI: 10.5489/Cuaj.5902 | 0.384 | |||
| 2019 | Chen S, Huang V, Xu X, Livingstone J, Soares F, Jeon J, Zeng Y, Hua JT, Petricca J, Guo H, Wang M, Yousif F, Zhang Y, Donmez N, Ahmed M, ... ... Fradet Y, et al. Widespread and Functional RNA Circularization in Localized Prostate Cancer. Cell. 176: 831-843.e22. PMID 30735634 DOI: 10.1016/J.Cell.2019.01.025 | 0.365 | |||
| 2019 | Levesque E, Caron P, Lacombe L, Turcotte V, Simonyan D, Fradet Y, Aprikian A, Saad F, Carmel M, Chevalier S, Guillemette C. A Comprehensive Analysis of Steroid Hormones and Progression of Localized High-Risk Prostate Cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 30733309 DOI: 10.1158/1055-9965.Epi-18-1002 | 0.454 | |||
| 2019 | Rouleau M, Lemire F, Déry M, Thériault B, Dubois G, Fradet Y, Toren P, Guillemette C, Lacombe L, Klotz L, Saad F, Guérette D, Pouliot F. Discordance between testosterone measurement methods in castrated prostate cancer patients. Endocrine Connections. PMID 30673630 DOI: 10.1530/Ec-18-0476 | 0.334 | |||
| 2019 | Fervaha* G, Izard J, Tripp D, Rajan S, Karampatos S, Shayegan B, Matsumoto E, Niazi T, Chen-Tournoux A, Fradet V, Fradet Y, Delouya G, Taussky D, Lavallee L, Johnson C, et al. PD30-03 PSYCHOLOGICAL MORBIDITY ASSOCIATED WITH A NEW DIAGNOSIS OF PROSTATE CANCER: RATES AND PREDICTORS OF DEPRESSIVE SYMPTOMS IN THE RADICAL PC STUDY Journal of Urology. 201. DOI: 10.1097/01.Ju.0000556135.36362.37 | 0.36 | |||
| 2019 | Fervaha* G, Izard J, Tripp D, Rajan S, Karampatos S, Shayegan B, Matsumoto E, Niazi T, Chen-Tournoux A, Fradet V, Fradet Y, Duceppe E, Lavallee L, Johnson C, Chin J, et al. MP22-15 DEPRESSION IN PROSTATE CANCER PATIENTS STARTING ANDROGEN DEPRIVATION THERAPY Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555600.69863.72 | 0.424 | |||
| 2019 | Necchi A, Fradet Y, Bellmunt J, de Wit R, Lee J, Fong L, Vozelgang N, Climent M, Petrylak D, Choueiri T, Gerritsen W, Gurney H, Quinn D, Culine S, Sternberg C, et al. Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC) Annals of Oncology. 30: v366-v367. DOI: 10.1093/Annonc/Mdz249.018 | 0.359 | |||
| 2019 | Trudel D, Grosset A, Dallaire F, Nguyen T, Kougioumoutzakis A, Azzi F, Aubertin K, Saad F, Latour M, Albadine R, Boutros P, Fraser M, Bristow RG, Kwast Tvd, Benzerdjeb N, ... ... Fradet Y, et al. Raman microscopy for the identification of an aggressive variant of prostate cancer, intraductal carcinoma of the prostate Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz239.002 | 0.419 | |||
| 2018 | Gevariya N, Besançon M, Robitaille K, Picard V, Diabaté L, Alesawi A, Julien P, Fradet Y, Bergeron A, Fradet V. Omega-3 fatty acids decrease prostate cancer progression associated with an anti-tumor immune response in eugonadal and castrated mice. The Prostate. PMID 30073695 DOI: 10.1002/Pros.23706 | 0.395 | |||
| 2018 | Toren P, Hoffman A, Ding K, Joncas FH, Turcotte V, Caron P, Pouliot F, Fradet Y, Levesque E, Guillemette C, Klotz LH. Serum sex steroids as prognostic biomarkers in patients receiving androgen deprivation therapy for recurrent prostate cancer: a post-hoc analysis of the PR.7 trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30021911 DOI: 10.1158/1078-0432.Ccr-18-1187 | 0.456 | |||
| 2018 | Pelletier J, Cyr SJ, Julien AS, Fradet Y, Lacombe L, Toren P. Contemporary outcomes of palliative transurethral resection of the prostate in patients with locally advanced prostate cancer. Urologic Oncology. PMID 29880461 DOI: 10.1016/J.Urolonc.2018.05.004 | 0.443 | |||
| 2018 | Locke JA, Hamidizadeh R, Kassouf W, Ricardo Rendon R, Bell D, Izawa J, Joseph Chin J, Kapoor A, Shayegen B, Lattouf JB, Saad F, Lacombe L, Fradet Y, Fairey A, Jacobson NE, et al. Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinoma. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 29688881 DOI: 10.5489/Cuaj.5377 | 0.32 | |||
| 2018 | Lavallée E, Bergeron M, Buteau FA, Blouin AC, Duchesnay N, Dujardin T, Tiguert R, Lacombe L, Fradet V, Makao-Nguile M, Fradet Y, Beauregard JM, Pouliot F. Increased Prostate Cancer Glucose Metabolism Detected byF-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration. European Urology Focus. PMID 29609897 DOI: 10.1016/J.Euf.2018.03.008 | 0.381 | |||
| 2018 | Kassouf W, Aprikian A, Saad F, Breau RH, Kulkarni G, Guttman DM, Bagshaw K, Izawa J, Eapen L, Fairey A, So A, North S, Rendon R, Sridhar SS, Brimo F, ... ... Fradet Y, et al. Improving patient journey and quality of care: Summary from the 2nd Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 29603921 DOI: 10.5489/Cuaj.5246 | 0.348 | |||
| 2018 | Trinh VQ, Sirois J, Benzerdjeb N, Mansoori BK, Grosset AA, Albadine R, Latour M, Mes-Masson AM, Hovington H, Bergeron A, Ladouceur M, Fradet Y, Saad F, Trudel D. The impact of intraductal carcinoma of the prostate on the site and timing of recurrence and cancer-specific survival. The Prostate. PMID 29603326 DOI: 10.1002/Pros.23513 | 0.465 | |||
| 2018 | Vaughn DJ, Bellmunt J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, et al. Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017769562. PMID 29590008 DOI: 10.1200/Jco.2017.76.9562 | 0.304 | |||
| 2018 | Bellmunt J, Wit RD, Vaughn DJ, Fradet Y, Lee J, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, et al. Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC). Journal of Clinical Oncology. 36: 410-410. DOI: 10.1200/Jco.2018.36.6_Suppl.410 | 0.311 | |||
| 2018 | Fradet Y, Bellmunt J, De Wit R, Vaughn DJ, Lee J, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen WR, Gurney H, Quinn DI, Culine S, et al. Pembrolizumab (pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial. Journal of Clinical Oncology. 36: 4521-4521. DOI: 10.1200/Jco.2018.36.15_Suppl.4521 | 0.327 | |||
| 2018 | Toren P, Hoffman A, Ding K, Joncas F, Pouliot F, Fradet Y, Lévesque É, Guillemette C, Klotz L. Abstract A072: Serum sex steroids as prognostic biomarkers in patients receiving androgen-deprivation therapy for recurrent prostate cancer post-radiotherapy: A post hoc analysis of the PR.7 trial Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-A072 | 0.454 | |||
| 2018 | Bellmunt J, de Wit R, Vaughn D, Fradet Y, Lee J, Fong L, Vogelzang N, Climent M, Petrylak D, Choueiri T, Necchi A, Gerritsen W, Gurney H, Quinn D, Culine S, et al. Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator’s choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045 Annals of Oncology. 29: viii320-viii321. DOI: 10.1093/Annonc/Mdy283.110 | 0.379 | |||
| 2018 | Lavallee E, Bergeron M, Buteau F, Duchesnay N, Blouin A, Fradet Y, Dujardin T, Tiguert R, Lacombe L, Fradet V, Makao-Nguile M, Beauregard J, Pouliot F. Increased prostate cancer glucose metabolism detected by FDG-PET/CT in localised Gleason 8-10 prostate cancers identifies very high-risk patients for early recurrence and resistance to castration European Urology Supplements. 17: e1510. DOI: 10.1016/S1569-9056(18)31890-6 | 0.414 | |||
| 2018 | Lachance G, Geveriya N, Robitaille K, Bergeron A, Picard V, Leclerc M, Joly C, Fradet Y, Droit A, Marette A, Fradet V. MP70-17 DECIPHERING THE EFFECTS OF OMEGA-3 FATTY ACID SUPPLEMENTS ON PROSTATE CANCER Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.2261 | 0.387 | |||
| 2017 | Fradet V, Toren P, Nguile-Makao M, Lodde M, Lévesque J, Léger C, Caron A, Bergeron A, Ben-Zvi T, Lacombe L, Pouliot F, Tiguert R, Dujardin T, Fradet Y. Prognostic value of urinary PCA3 during active surveillance of low-risk prostate cancer in patients receiving 5α-reductase inhibitors. Bju International. PMID 28972698 DOI: 10.1111/Bju.14041 | 0.429 | |||
| 2017 | Morin F, Beauregard JM, Bergeron M, Nguile Makao M, Lacombe L, Fradet V, Fradet Y, Pouliot F. Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy. European Urology Focus. PMID 28753860 DOI: 10.1016/J.Euf.2017.02.007 | 0.367 | |||
| 2017 | Chua MLK, Lo W, Pintilie M, Murgic J, Lalonde E, Bhandari V, Mahamud O, Gopalan A, Kweldam CF, van Leenders GJLH, Verhoef EI, Hoogland AM, Livingstone J, Berlin A, Dal Pra A, ... ... Fradet Y, et al. A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. European Urology. PMID 28511883 DOI: 10.1016/J.Eururo.2017.04.034 | 0.435 | |||
| 2017 | Khare SR, Aprikian A, Black P, Blais N, Booth C, Brimo F, Chin J, Chung P, Drachenberg D, Eapen L, Fairey A, Fleshner N, Fradet Y, Gotto G, Izawa J, et al. Quality indicators in the management of bladder cancer: A modified Delphi study. Urologic Oncology. PMID 28065393 DOI: 10.1016/J.Urolonc.2016.12.003 | 0.337 | |||
| 2017 | Morin F, Beauregard J, Bergeron M, Nguilé-Makao M, Lacombe L, Fradet V, Fradet Y, Pouliot F. Serial FDG-PET imaging of metastatic prostate cancers reveals intrapatient intermetastases polyclonality through same patient heterogeneous responses to systemic therapy. Journal of Clinical Oncology. 35: e590-e590. DOI: 10.1200/Jco.2017.35.6_Suppl.E590 | 0.359 | |||
| 2017 | Bajorin DF, Wit RD, Vaughn DJ, Fradet Y, Lee J, Fong L, Vogelzang NJ, Climent MÁ, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, et al. Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC). Journal of Clinical Oncology. 35: 4501-4501. DOI: 10.1200/Jco.2017.35.15_Suppl.4501 | 0.305 | |||
| 2017 | Mahamud O, Chua MLK, Supiot S, Lalonde E, Pra AD, Berlin A, Orain M, Picard V, Hovington H, Bergeron A, Fradet Y, Têtu B, Zafarana G, Meng A, Livingstone J, et al. Abstract A28: Mutational landscape of TP53 in localized prostate cancer Molecular Cancer Research. 15. DOI: 10.1158/1557-3125.Dnarepair16-A28 | 0.431 | |||
| 2017 | Wit Rd, Vaughn DJ, Fradet Y, Lee J, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen WR, Gurney H, Quinn DI, Culine S, Sternberg CN, et al. LBA37_PRPembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): Mature results from the phase 3 KEYNOTE-045 trial Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx440.031 | 0.372 | |||
| 2017 | Petrylak D, Vogelzang NJ, Fradet Y, Bajorin D, Wit Rd, Vaughn DJ, Lee J, Fong L, Climent, Necchi A, Gerritsen WR, Gurney H, Quinn DI, Culine S, Sternberg CN, et al. 851PDSubgroup analyses from KEYNOTE-045: Pembrolizumab (pembro) versus individual investigator’s choice of chemotherapy (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (uc) Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx371.006 | 0.391 | |||
| 2017 | Necchi A, Bellmunt J, Wit RD, Vaughn D, Fradet Y, Lee JL, Fong L, Vogelzang N, Climent M, Petrylak D, Choueiri T, Gerritsen W, Gurney H, Quinn D, Culine S, et al. Pembrolizumab vs investigator-choice chemotherapy for previously treated advanced urothelial cancer: Phase 3 KEYNOTE-045 study European Journal of Cancer. 72. DOI: 10.1016/S0959-8049(17)30092-8 | 0.369 | |||
| 2017 | Haider M, Mayr R, Fritsche H, Ladurner C, Pycha A, Comploj E, Lemire F, Lacombe L, Fradet Y, Lodde M. Mp21-08 The Use Of Antibiotic Prophylaxis In Patients Undergoing Radical Cystectomy For Bladder Cancer The Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.3270 | 0.417 | |||
| 2016 | Lalonde E, Alkallas R, Chua ML, Fraser M, Haider S, Meng A, Zheng J, Yao CQ, Picard V, Orain M, Hovington H, Murgic J, Berlin A, Lacombe L, Bergeron A, ... Fradet Y, et al. Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. European Urology. PMID 27815082 DOI: 10.1016/J.Eururo.2016.10.013 | 0.42 | |||
| 2016 | Jain P, Neveu B, Velot L, Wu L, Fradet Y, Pouliot F. Bioluminescence Microscopy as a Method to Measure Single Cell Androgen Receptor Activity Heterogeneous Responses to Antiandrogens. Scientific Reports. 6: 33968. PMID 27678181 DOI: 10.1038/Srep33968 | 0.305 | |||
| 2016 | Scheid E, Major P, Bergeron A, Finn OJ, Salter RD, Eady R, Yassine-Diab B, Favre D, Peretz Y, Landry C, Hotte S, Mukherjee S, Dekaban GA, Fink C, Foster P, ... ... Fradet Y, et al. Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Non-Metastatic Castrate Resistant Prostate Cancer. Cancer Immunology Research. PMID 27604597 DOI: 10.1158/2326-6066.Cir-15-0189 | 0.353 | |||
| 2016 | Kassouf W, Aprikian A, Black P, Kulkarni G, Izawa J, Eapen L, Fairey A, So A, North S, Rendon R, Sridhar SS, Alam T, Brimo F, Blais N, Booth C, ... ... Fradet Y, et al. Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 10: E46-80. PMID 26977213 DOI: 10.5489/Cuaj.3583 | 0.407 | |||
| 2016 | Ayari C, Besançon M, Bergeron A, LaRue H, Bussières V, Fradet Y. Poly(I:C) potentiates Bacillus Calmette-Guérin immunotherapy for bladder cancer. Cancer Immunology, Immunotherapy : Cii. PMID 26759009 DOI: 10.1007/S00262-015-1789-Y | 0.37 | |||
| 2016 | Chua M, Lalonde E, Mahamud O, Berlin A, Pra AD, Orain M, Picard V, Hovington H, Bergeron A, Fradet Y, Têtu B, Meng A, Zhang J, Zafarana G, Livingstone J, et al. Copy number alterations of DNA mismatch repair (MMR) genes as novel prognostic markers in localised prostate cancer (CaP). Journal of Clinical Oncology. 34: 96-96. DOI: 10.1200/Jco.2016.34.2_Suppl.96 | 0.373 | |||
| 2016 | So J, Chua M, Lalonde E, Mahamud O, Berlin A, Dal Pra A, Orain M, Hovington H, Bergeron A, Fradet Y, Têtu B, Meng A, Zhang J, Zafarana G, Livingstone J, et al. Prognostic value of copy-number alterations of the Cohesin complex in intermediate-risk prostate cancer recurrence. Journal of Clinical Oncology. 34: 49-49. DOI: 10.1200/Jco.2016.34.2_Suppl.49 | 0.429 | |||
| 2016 | Mahamud O, Chua M, Lalonde E, So J, Dal Pra A, Berlin A, Orain M, Picard V, Hovington H, Bergeron A, Fradet Y, Têtu B, Zafarana G, Meng A, Livingstone J, et al. Copy number alterations of P53, RB1, and MDM2 as prognostic markers in intermediate-risk prostate cancer. Journal of Clinical Oncology. 34: 117-117. DOI: 10.1200/Jco.2016.34.2_Suppl.117 | 0.369 | |||
| 2016 | Chua M, Murgic J, Pintilie M, Lalonde E, Berlin A, Livingstone J, Dal Pra A, Meng A, Zhang J, Fradet Y, Têtu B, Fleshner NE, Fraser M, Boutros P, van der Kwast T, et al. Combinatorial genomic and pathological indices for integrated stratification of unfavorable intermediate-risk prostate cancer. Journal of Clinical Oncology. 34: 5051-5051. DOI: 10.1200/Jco.2016.34.15_Suppl.5051 | 0.424 | |||
| 2016 | Althammer S, Steele K, Rebelatto M, Tan TH, Wiestler T, Schmidt G, Higgs B, Li X, Shi L, Jin X, Antal J, Gupta A, Ranade K, Binning G, Bellmunt J, ... ... Fradet Y, et al. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts Journal For Immunotherapy of Cancer. 4. DOI: 10.1186/S40425-016-0191-4 | 0.336 | |||
| 2016 | Jain P, Neveu B, Fradet Y, FP. Abstract 4764: Development of a multigenic bioluminescence imaging system to detect prostate cancer cells and assess their response to therapy Cancer Research. 76: 4764-4764. DOI: 10.1158/1538-7445.Am2016-4764 | 0.43 | |||
| 2016 | Chua MLK, Murgic J, Pintilie M, Lalonde E, Kweldam C, Lo W, Berlin A, Pra AD, Orain M, Picard V, Hovington H, Begeron A, Fradet Y, Tetu B, Livingstone J, et al. Abstract 4339: Prognostic significance of copy number alteration burden in unfavorable intermediate-risk prostate cancers harboring intraductal carcinoma and cribriform architecture Cancer Research. 76: 4339-4339. DOI: 10.1158/1538-7445.Am2016-4339 | 0.427 | |||
| 2016 | Fraser ME, Kwast Tvd, McPherson J, Collins CC, Fradet Y, Tetu B, Bergeron A, Bristow RG, Boutros PC. Abstract 118: A comprehensive profile of the genomic architecture of curable prostate cancer Cancer Research. 76: 118-118. DOI: 10.1158/1538-7445.Am2016-118 | 0.455 | |||
| 2016 | So J, Chua M, Lalonde E, Mahamud O, Berlin A, Pra AD, Orain M, Hovington H, Bergeron A, Fradet Y, Têtu B, Meng A, Zhang J, Zafarana G, Pintilie M, et al. 227: Prognostic Significance of Tonsl Expression and the Homologous Recombination Pathway in Intermediate-Risk Prostate Cancer Recurrence Radiotherapy and Oncology. 120: S82-S83. DOI: 10.1016/S0167-8140(16)33626-X | 0.459 | |||
| 2015 | Lacombe L, Fradet V, Levesque E, Pouliot F, Larue H, Bergeron A, Hovington H, Caron A, Nguile-Makao M, Harvey M, Fradet Y, Guillemette C. Phase II drug metabolizing polymorphisms and smoking status predict recurrence of non-muscle invasive bladder cancer: a gene-smoking interaction. Cancer Prevention Research (Philadelphia, Pa.). PMID 26645279 DOI: 10.1158/1940-6207.Capr-15-0069 | 0.333 | |||
| 2015 | Neveu B, Jain P, Têtu B, Wu L, Fradet Y, Pouliot F. A PCA3 gene-based transcriptional amplification system targeting primary prostate cancer. Oncotarget. PMID 26594800 DOI: 10.18632/Oncotarget.6360 | 0.417 | |||
| 2015 | Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, Skinner E, Denzinger S, Fradet Y, Isbarn H, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Tilki D, et al. Corrigendum to "Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort" [Eur Urol 2010;57:300-9]. European Urology. 68: 171. PMID 26088736 DOI: 10.1016/J.Eururo.2015.02.007 | 0.324 | |||
| 2015 | Desmeules P, Hovington H, Nguilé-Makao M, Léger C, Caron A, Lacombe L, Fradet Y, Têtu B, Fradet V. Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy. Diagnostic Pathology. 10: 67. PMID 26070608 DOI: 10.1186/S13000-015-0294-0 | 0.415 | |||
| 2015 | Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, et al. Impact of Bone-targeted Therapies in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302. European Urology. PMID 25985882 DOI: 10.1016/J.Eururo.2015.04.032 | 0.308 | |||
| 2015 | Escamilla J, Schokrpur S, Liu C, Priceman SJ, Moughon D, Jiang Z, Pouliot F, Magyar C, Sung JL, Xu J, Deng G, West BL, Bollag G, Fradet Y, Lacombe L, et al. CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy. Cancer Research. 75: 950-62. PMID 25736687 DOI: 10.1158/0008-5472.Can-14-0992 | 0.301 | |||
| 2015 | Gill S, Haince JF, Shi Q, Pavey ES, Beaudry G, Sargent DJ, Fradet Y. Prognostic Value of Molecular Detection of Lymph Node Metastases After Curative Resection of Stage II Colon Cancer: A Systematic Pooled Data Analysis. Clinical Colorectal Cancer. 14: 99-105. PMID 25619805 DOI: 10.1016/J.Clcc.2014.12.005 | 0.344 | |||
| 2015 | Belledant A, Hovington H, Brisson H, Têtu B, Fradet Y, Lacombe L, Caron P, Guillemette C, Lévesque E. Abstract 3448: Overexpression of the steroid inactivating UGT2B28 enzyme is associated with high circulating androgens, tumor aggressiveness and adverse prostate cancer outcome Endocrinology. 75: 3448-3448. DOI: 10.1158/1538-7445.Am2015-3448 | 0.422 | |||
| 2015 | Fraser ME, Sabelnykova VY, Yamaguchi TN, Meng A, Heisler LE, Zhang J, Livingstone J, Huang V, Masella AP, Yousif F, Xie M, Harding NJ, Lin X, Kong H, Prokopec SD, ... ... Fradet Y, et al. Abstract 2966: The mutational landscape of localized gleason 6 and 7 prostate cancer Cancer Research. 75: 2966-2966. DOI: 10.1158/1538-7445.Am2015-2966 | 0.428 | |||
| 2015 | Jain P, Neveu B, Fradet Y, Pouliot F. Abstract 206: Development of a molecular imaging system based on the transcriptional activity of the DD3/PCA3 non-coding RNA for imaging specifically the prostate cancer cells Cancer Research. 75: 206-206. DOI: 10.1158/1538-7445.Am2015-206 | 0.417 | |||
| 2015 | Haince J, Beaudry G, Paquet E, Aaron L, Sabbagh R, Fradet V, Fleshner N, Fradet Y. 322 Development and validation of a post-DRE urine-based multigene signature for detection of aggressive prostate cancer prior to biopsy European Urology Supplements. 14: e322. DOI: 10.1016/S1569-9056(15)60319-0 | 0.43 | |||
| 2015 | Jain P, Neveu B, Fradet Y, Pouliot F. Mp61-13 Development Of A Molecular Imaging System Based On The Transcriptional Activity Of The Dd3/Pca3 Non-Coding Rna For Imaging Specifically The Prostate Cancer Cells The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2194 | 0.35 | |||
| 2015 | Dean L, Fairey A, Jacobsen N, Tanguay S, Rendon R, Bell D, Izawa J, Chin J, Kapoor A, Shayegan B, Matsumoto E, Black P, So A, Lattouf J, Saad F, ... ... Fradet Y, et al. Mp57-20 Variant Histology Does Not Predict Survival Outcomes After Radical Nephroureterectomy For Upper Tract Urothelial Carcinoma: Results From The Canadian Upper Tract Collaboration The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2008 | 0.324 | |||
| 2015 | Haince J, Beaudry G, Paquet E, Aaron L, Sabbagh R, Fradet V, Fleshner N, Fradet Y. MP1-03 VALIDATED URINE-BASED MULTIGENE SIGNATURE FOR DETECTION OF AGGRESSIVE PROSTATE CANCER Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.166 | 0.434 | |||
| 2014 | Kapoor A, Dason S, Allard CB, Shayegan B, Lacombe L, Rendon R, Jacobsen NE, Fairey A, Izawa J, Black P, Tanguay S, Chin J, So A, Lattouf JB, Bell D, ... ... Fradet Y, et al. The impact of method of distal ureter management during radical nephroureterectomy on tumour recurrence. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 8: E845-52. PMID 25485014 DOI: 10.5489/Cuaj.1985 | 0.343 | |||
| 2014 | Sargent DJ, Shi Q, Gill S, Louvet C, Everson RB, Kellner U, Clancy TE, Pipas JM, Resnick MB, Meyers MO, Wu TT, Huntsman D, Validire P, Farooq U, Pavey ES, ... ... Fradet Y, et al. Molecular testing for lymph node metastases as a determinant of colon cancer recurrence: results from a retrospective multicenter study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4361-9. PMID 24919572 DOI: 10.1158/1078-0432.Ccr-13-2659 | 0.393 | |||
| 2014 | Neveu B, Moreel X, Deschênes-Rompré MP, Bergeron A, LaRue H, Ayari C, Fradet Y, Fradet V. IL-8 secretion in primary cultures of prostate cells is associated with prostate cancer aggressiveness. Research and Reports in Urology. 6: 27-34. PMID 24892030 DOI: 10.2147/Rru.S58643 | 0.42 | |||
| 2014 | Huang SP, Lévesque E, Guillemette C, Yu CC, Huang CY, Lin VC, Chung IC, Chen LC, Laverdière I, Lacombe L, Fradet Y, Chang TY, Lee HZ, Juang SH, Bao BY. Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer. International Journal of Cancer. Journal International Du Cancer. 135: 2661-7. PMID 24740842 DOI: 10.1002/Ijc.28904 | 0.402 | |||
| 2014 | Lévesque E, Laverdière I, Audet-Walsh E, Caron P, Rouleau M, Fradet Y, Lacombe L, Guillemette C. Steroidogenic germline polymorphism predictors of prostate cancer progression in the estradiol pathway. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2971-83. PMID 24682418 DOI: 10.1158/1078-0432.Ccr-13-2567 | 0.439 | |||
| 2014 | Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). European Urology. 66: 815-25. PMID 24647231 DOI: 10.1016/J.Eururo.2014.02.056 | 0.32 | |||
| 2014 | Messer JC, Shariat SF, Dinney CP, Novara G, Fradet Y, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Lotan Y, Skinner EC, Tilki D, Ficarra V, Volkmer BG, Isbarn H, et al. Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. Urology. 83: 863-7. PMID 24485993 DOI: 10.1016/J.Urology.2013.10.060 | 0.412 | |||
| 2014 | Bachir BG, Aprikian AG, Izawa JI, Chin JL, Fradet Y, Fairey A, Estey E, Jacobsen N, Rendon R, Cagiannos I, Lacombe L, Lattouf JB, Kapoor A, Matsumoto E, Saad F, et al. Effect of body mass index on the outcomes of patients with upper and lower urinary tract cancers treated by radical surgery: results from a Canadian multicenter collaboration. Urologic Oncology. 32: 441-8. PMID 24412632 DOI: 10.1016/J.Urolonc.2013.10.016 | 0.368 | |||
| 2014 | Kluth LA, Rieken M, Xylinas E, Kent M, Rink M, Rouprêt M, Sharifi N, Jamzadeh A, Kassouf W, Kaushik D, Boorjian SA, Roghmann F, Noldus J, Masson-Lecomte A, Vordos D, ... ... Fradet Y, et al. Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients. European Urology. 66: 913-9. PMID 24331151 DOI: 10.1016/J.Eururo.2013.11.040 | 0.364 | |||
| 2014 | Lee RK, Abol-Enein H, Artibani W, Bochner B, Dalbagni G, Daneshmand S, Fradet Y, Hautmann RE, Lee CT, Lerner SP, Pycha A, Sievert KD, Stenzl A, Thalmann G, Shariat SF. Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. Bju International. 113: 11-23. PMID 24330062 DOI: 10.1111/Bju.12121 | 0.355 | |||
| 2014 | Lévesque É, Laverdière I, Lacombe L, Caron P, Rouleau M, Turcotte V, Têtu B, Fradet Y, Guillemette C. Importance of 5α-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 576-84. PMID 24277450 DOI: 10.1158/1078-0432.Ccr-13-1100 | 0.414 | |||
| 2014 | Yafi FA, Aprikian AG, Chin JL, Fradet Y, Izawa J, Estey E, Fairey A, Rendon R, Cagiannos I, Lacombe L, Lattouf JB, Saad F, Bell D, Drachenberg D, Kassouf W. Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer. World Journal of Urology. 32: 1295-301. PMID 24213922 DOI: 10.1007/S00345-013-1207-Z | 0.366 | |||
| 2014 | Ploussard G, Shariat SF, Dragomir A, Kluth LA, Xylinas E, Masson-Lecomte A, Rieken M, Rink M, Matsumoto K, Kikuchi E, Klatte T, Boorjian SA, Lotan Y, Roghmann F, Fairey AS, ... Fradet Y, et al. Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time. European Urology. 66: 361-70. PMID 24139235 DOI: 10.1016/J.Eururo.2013.09.050 | 0.399 | |||
| 2014 | Yafi FA, Tanguay S, Rendon R, Jacobsen N, Fairey A, Izawa J, Kapoor A, Black P, Lacombe L, Chin J, So A, Lattouf JB, Bell D, Fradet Y, Saad F, et al. Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome. Urologic Oncology. 32: 31.e17-24. PMID 23428535 DOI: 10.1016/J.Urolonc.2012.11.014 | 0.332 | |||
| 2014 | Kluth L, Rieken M, Xylinas E, Kent M, Rink M, Rouprêt M, Sharifi N, Amzadeh A, Kassouf W, Kaushik D, Boorjian S, Roghmann F, Noldus J, Masson-Lecomte A, Vordos D, ... ... Fradet Y, et al. 897 Gender-specific differences in clinicopathologic outcomes following radical cystectomy: An international multi-institutional study of over 8,000 patients European Urology Supplements. 13: e897-e897a. DOI: 10.1016/S1569-9056(14)60883-6 | 0.318 | |||
| 2014 | Ben-Zvi T, Desmeules P, Hovington H, Léger C, Caron A, Lacombe L, Fradet Y, Têtu B, Fradet V. MP79-11 IMPACT OF KI67 LABELING INDEX ON PROGRESSION AND DEATH OF PROSTATE CANCER POST-PROSTATECTOMY: COMPARISON OF VISUAL AND AUTOMATED SCORING Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.2514 | 0.403 | |||
| 2014 | Shore N, Rathkopf D, Smith MR, de Bono JS, Logothetis C, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Griffin T, Park YC, et al. PD27-01 EFFICACY AND LONG-TERM SAFETY ANALYSIS OF STUDY COU-AA-302: ABIRATERONE ACETATE PLUS PREDNISONE IN CHEMOTHERAPY-NAÏVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.2100 | 0.36 | |||
| 2013 | Smith MR, De Bono JS, Logothetis C, Shore ND, De Souza PL, Fizazi K, Mulders P, Mainwaring PN, Hainsworth JD, Beer TM, North SA, Fradet Y, Griffin TW, Park YC, Kheoh TS, et al. Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 5. PMID 28137142 DOI: 10.1200/Jco.2013.31.6_Suppl.5 | 0.401 | |||
| 2013 | Bachir BG, Aprikian AG, Fradet Y, Chin JL, Izawa J, Rendon R, Estey E, Fairey A, Cagiannos I, Lacombe L, Lattouf JB, Bell D, Saad F, Drachenberg D, Kassouf W. Regional differences in practice patterns and outcomes in patients treated with radical cystectomy in a universal healthcare system. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 7: E667-72. PMID 24282454 DOI: 10.5489/Cuaj.201 | 0.332 | |||
| 2013 | LaRue H, Ayari C, Bergeron A, Fradet Y. Toll-like receptors in urothelial cells--targets for cancer immunotherapy. Nature Reviews. Urology. 10: 537-45. PMID 23979666 DOI: 10.1038/Nrurol.2013.153 | 0.329 | |||
| 2013 | Fairey AS, Jacobsen NE, Estey E, Tanguay S, Rendon R, Bell D, Izawa J, Chin J, Kapoor A, Matsumoto E, Black P, So A, Lattouf JB, Saad F, Drachenberg D, ... ... Fradet Y, et al. Comorbidity status does not independently predict survival outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. European Urology. 64: 518-9. PMID 23796500 DOI: 10.1016/J.Eururo.2013.06.014 | 0.317 | |||
| 2013 | Tilki D, Brausi M, Colombo R, Evans CP, Fradet Y, Fritsche HM, Lerner SP, Sagalowsky A, Shariat SF, Bochner BH. Lymphadenectomy for bladder cancer at the time of radical cystectomy. European Urology. 64: 266-76. PMID 23648149 DOI: 10.1016/J.Eururo.2013.04.036 | 0.399 | |||
| 2013 | Ayari C, LaRue H, Hovington H, Caron A, Bergeron A, Têtu B, Fradet V, Fradet Y. High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer. Human Pathology. 44: 1630-7. PMID 23574787 DOI: 10.1016/J.Humpath.2013.01.014 | 0.398 | |||
| 2013 | Xylinas E, Rink M, Robinson BD, Lotan Y, Babjuk M, Brisuda A, Green DA, Kluth LA, Pycha A, Fradet Y, Faison T, Lee RK, Karakiewicz PI, Zerbib M, Scherr DS, et al. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. European Journal of Cancer (Oxford, England : 1990). 49: 1889-97. PMID 23466126 DOI: 10.1016/J.Ejca.2013.02.001 | 0.36 | |||
| 2013 | Williams AK, Kassouf W, Chin J, Rendon R, Jacobsen N, Fairey A, Kapoor A, Black P, Lacombe L, Tanguay S, So A, Lattouf JB, Bell D, Fradet Y, Saad F, et al. Multifocality rather than tumor location is a prognostic factor in upper tract urothelial carcinoma. Urologic Oncology. 31: 1161-5. PMID 23415596 DOI: 10.1016/J.Urolonc.2011.12.004 | 0.367 | |||
| 2013 | Lévesque É, Huang SP, Audet-Walsh É, Lacombe L, Bao BY, Fradet Y, Laverdière I, Rouleau M, Huang CY, Yu CC, Caron P, Guillemette C. Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 699-709. PMID 23186779 DOI: 10.1158/1078-0432.Ccr-12-2812 | 0.436 | |||
| 2013 | Mauermann J, Fradet V, Fradet Y. Reply from authors re: Martin Spahn, Steven Joniau. Positive surgical margin at radical prostatectomy: futile or surgeon-dependent predictor of prostate cancer death? Eur Urol 2013;64:26-8: adjuvant versus salvage radiotherapy in patients with positive surgical margins at radical prostatectomy: that is the question. European Urology. 64: 28-9. PMID 23159455 DOI: 10.1016/J.Eururo.2012.10.047 | 0.428 | |||
| 2013 | Fairey AS, Kassouf W, Estey E, Tanguay S, Rendon R, Bell D, Izawa J, Chin J, Kapoor A, Matsumoto E, Black P, So A, Lattouf JB, Saad F, Drachenberg D, ... ... Fradet Y, et al. Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration. Bju International. 112: 791-7. PMID 23148712 DOI: 10.1111/J.1464-410X.2012.11474.X | 0.357 | |||
| 2013 | Mauermann J, Fradet V, Lacombe L, Dujardin T, Tiguert R, Tetu B, Fradet Y. The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients. European Urology. 64: 19-25. PMID 22901983 DOI: 10.1016/J.Eururo.2012.08.002 | 0.32 | |||
| 2013 | Hansen J, Auprich M, Ahyai SA, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Fisch M, Abbou CC, Schalken JA, Fradet Y, Marks LS, Ellis W, et al. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. European Urology. 63: 201-9. PMID 22854248 DOI: 10.1016/J.Eururo.2012.07.030 | 0.417 | |||
| 2013 | Lodde M, Lacombe L, Naselli A, Puppo P, Mian M, Fradet Y. Long-term PSA-free survival and castration-free survival with delayed antiandrogen therapy in patients with one versus two or more positive nodes at prostatectomy. World Journal of Urology. 31: 293-7. PMID 22270262 DOI: 10.1007/S00345-012-0827-Z | 0.337 | |||
| 2013 | Kassouf W, Svatek RS, Shariat SF, Novara G, Lerner SP, Fradet Y, Bastian PJ, Aprikian A, Karakiewicz PI, Fritsche HM, Dinney CP, Tilki D, Kamat AM, Izawa JI, Ficarra V, et al. Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. Urologic Oncology. 31: 480-6. PMID 21478035 DOI: 10.1016/J.Urolonc.2011.02.011 | 0.364 | |||
| 2013 | Sandhu GS, Aprikian A, Chin J, Fradet Y, Izawa J, Estey E, Fairey A, Rendon R, Cagiannos I, Lacombe L, Lattouf J, Bell D, Kassouf W, Drachenberg D. Outcomes of pT0N0 at radical cystectomy: The Canadian Bladder Canadian Urological Association Journal. 6: E116-E120. DOI: 10.5489/Cuaj.433 | 0.3 | |||
| 2013 | Klotz L, Fradet Y, Goldenberg L, Tanguay S. Sharing the responsibility of prostate cancer risk reduction Canadian Urological Association Journal. 3: 91. DOI: 10.5489/Cuaj.1211 | 0.44 | |||
| 2013 | Rathkopf DE, Smith MR, Bono JSD, Logothetis C, Shore N, Souza PLD, Fizazi K, Mulders P, Mainwaring PN, Hainsworth JD, Beer TM, North SA, Fradet Y, Griffin TW, Park YC, et al. Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302). Journal of Clinical Oncology. 31: 5009-5009. DOI: 10.1200/Jco.2013.31.15_Suppl.5009 | 0.313 | |||
| 2013 | Sargent DJ, Shi Q, Gill S, Louvet C, Everson RB, Kellner U, Clancy TE, Pipas JM, Resnick MB, Meyers MO, Huntsman D, Validire P, Farooq U, Pavey ES, Haince J, ... ... Fradet Y, et al. Guanylyl cyclase C (GCC) expression in lymph nodes (LNs) as a determinant of recurrence in stage II colon cancer (CC) patients (pts). Journal of Clinical Oncology. 31: 3639-3639. DOI: 10.1200/Jco.2013.31.15_Suppl.3639 | 0.348 | |||
| 2013 | Burger M, Grossman H, Droller M, Schmidbauer J, Hermann G, Drăgoescu O, Ray E, Witjes F, Karl A, Stenzl A, Fradet Y, Burgués J, Jocham D. 577 Photodynamic diagnosis of non-muscle invasive bladder cancer with hexaminolevulinate cystoscopy: A meta-analysis European Urology Supplements. 12: e577. DOI: 10.1016/S1569-9056(13)61060-X | 0.353 | |||
| 2013 | Van Poppel H, Rathkopf D, Smith M, De Bono J, Logothetis C, Shore N, De Souza P, Fizazi K, Mulders P, Mainwaring P, Hainsworth J, Beer T, North S, Fradet Y, Griffin T, et al. 97 Updated interim analysis (IA): Results of randomized phase 3 study COU-AA-302 of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy European Urology Supplements. 12: e97-e98. DOI: 10.1016/S1569-9056(13)60589-8 | 0.426 | |||
| 2013 | Blouin A, Rimac G, Bouchard F, Lemay C, Fradet V, Caron A, Fradet Y, Lacombe L, Dujardin T, Tigert R, Beauregard J, Pouliot F. 241 DETERMINATION OF THE ACCURACY OF FDG-PET/CT IN THE PRIMARY STAGING OF BIOLOGICAL HIGH RISK PROSTATE CANCERS BEFORE LOCAL THERAPIES: INCREASED UPTAKE ASSOCIATED WITH HIGHLY AGGRESSIVE TUMORS Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.1621 | 0.381 | |||
| 2012 | Sargent DJ, Shi Q, Resnick MB, Lyle S, Meyers MO, Goldar-Najafi A, Clancy TE, Gill S, Haince JF, Fradet Y. Evaluation of the prognostic value of guanylyl cyclase C (GCC) lymph node (LN) classification in patients with stage II colon cancer: A pooled analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 443. PMID 27983164 DOI: 10.1200/Jco.2012.30.4_Suppl.443 | 0.362 | |||
| 2012 | Power NE, Kassouf W, Bell D, Aprikian AG, Fradet Y, Lacombe L, Chin J, Izawa J, Estey E, Fairey A, Cagiannos I, Lattouf JB, Drachenberg D, Rendon RA. Natural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant chemotherapy in a contemporary North-American multi-institutional cohort. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 6: E217-23. PMID 23283097 DOI: 10.5489/cuaj.11012 | 0.416 | |||
| 2012 | Metcalfe M, Kassouf W, Rendon R, Bell D, Izawa J, Chin J, Kapoor A, Matsumoto E, Lattouf JB, Saad F, Lacombe L, Fradet Y, Fairey A, Jacobson NE, Drachenberg D, et al. Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in Canada. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 6: 455-62. PMID 23282664 DOI: 10.5489/Cuaj.12146 | 0.309 | |||
| 2012 | Xylinas E, Cha EK, Sun M, Rink M, Trinh QD, Novara G, Green DA, Pycha A, Fradet Y, Daneshmand S, Svatek RS, Fritsche HM, Kassouf W, Scherr DS, Faison T, et al. Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling. British Journal of Cancer. 107: 1826-32. PMID 23169335 DOI: 10.1038/Bjc.2012.464 | 0.405 | |||
| 2012 | Fradet Y. Radical prostatectomy is the most cost-effective primary treatment modality for men diagnosed with high-risk prostate cancer. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 6: 396-8. PMID 23093636 DOI: 10.5489/Cuaj.12272 | 0.474 | |||
| 2012 | Rink M, Shariat SF, Xylinas E, Fitzgerald JP, Hansen J, Green DA, Kamat AM, Novara G, Daneshmand S, Fradet Y, Tagawa ST, Bastian PJ, Kassouf W, Trinh QD, Karakiewicz PI, et al. Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy? World Journal of Urology. 30: 807-14. PMID 22832587 DOI: 10.1007/S00345-012-0910-5 | 0.32 | |||
| 2012 | Sandhu GS, Aprikian A, Chin J, Fradet Y, Izawa J, Estey E, Fairey A, Rendon R, Cagiannos I, Lacombe L, Lattouf JB, Bell D, Kassouf W, Drachenberg D. Outcomes of pT0N0 at radical cystectomy: The Canadian Bladder Cancer Network experience. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 6: E116-20. PMID 22709882 DOI: 10.5489/Cuaj.11276 | 0.41 | |||
| 2012 | Grossman HB, Stenzl A, Fradet Y, Mynderse LA, Kriegmair M, Witjes JA, Soloway MS, Karl A, Burger M. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. The Journal of Urology. 188: 58-62. PMID 22583635 DOI: 10.1016/J.Juro.2012.03.007 | 0.331 | |||
| 2012 | Klotz L, Chetner M, Chin J, Finelli T, Fleshner N, Fradet Y, Goldenberg L, Nickel JC, Siemens R, So A, Sugar L, Zlotta A, Klein E, Parnes H, Penson D. Canadian Consensus Conference: The FDA decision on the use of 5ARIs. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 6: 83-8. PMID 22511412 DOI: 10.5489/Cuaj.12058 | 0.445 | |||
| 2012 | Yafi FA, Aprikian AG, Fradet Y, Chin JL, Izawa J, Rendon R, Estey E, Fairey A, Cagiannos I, Lacombe L, Lattouf JB, Bell D, Saad F, Drachenberg D, Kassouf W. Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience. Bju International. 110: 1317-23. PMID 22500588 DOI: 10.1111/J.1464-410X.2012.11133.X | 0.43 | |||
| 2012 | Mason RJ, Kassouf W, Bell DG, Lacombe L, Kapoor A, Jacobsen N, Fairey A, Izawa J, Black P, Tanguay S, Chin J, So A, Lattouf JB, Saad F, Matsumoto E, ... ... Fradet Y, et al. The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience. Urology. 79: 840-5. PMID 22365453 DOI: 10.1016/J.Urology.2011.11.058 | 0.304 | |||
| 2012 | Kotb AF, Kovac E, Kassouf W, Chin J, Fradet Y, Izawa J, Estey E, Fairey A, Rendon R, Cagiannos I, Lacombe L, Lattouf JB, Bell D, Drachenberg D, Aprikian AG. Radical cystectomy for clinically muscle invasive bladder cancer: does prior non-invasive disease affect clinical outcomes? World Journal of Urology. 30: 761-7. PMID 22293934 DOI: 10.1007/S00345-012-0832-2 | 0.374 | |||
| 2012 | Audet-Walsh É, Bellemare J, Lacombe L, Fradet Y, Fradet V, Douville P, Guillemette C, Lévesque É. The impact of germline genetic variations in hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after prostatectomy. European Urology. 62: 88-96. PMID 22209174 DOI: 10.1016/J.Eururo.2011.12.021 | 0.399 | |||
| 2012 | Shariat SF, Chromecki TF, Cha EK, Karakiewicz PI, Sun M, Fradet Y, Isbarn H, Scherr DS, Bastian PJ, Pummer K, Fajkovic H, Sagalowsky AI, Ashfaq R, Doblinger M, Cote RJ, et al. Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers. The Journal of Urology. 187: 457-62. PMID 22177145 DOI: 10.1016/J.Juro.2011.10.031 | 0.383 | |||
| 2012 | Shariat SF, Ehdaie B, Rink M, Cha EK, Svatek RS, Chromecki TF, Fajkovic H, Novara G, David SG, Daneshmand S, Fradet Y, Lotan Y, Sagalowsky AI, Clozel T, Bastian PJ, et al. Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. European Urology. 61: 237-42. PMID 22033174 DOI: 10.1016/J.Eururo.2011.10.011 | 0.337 | |||
| 2012 | Chromecki TF, Mauermann J, Cha EK, Svatek RS, Fajkovic H, Karakiewicz PI, Lotan Y, Tilki D, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Novara G, Fritsche HM, Ficarra V, ... ... Fradet Y, et al. Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy World Journal of Urology. 30: 753-759. PMID 22009117 DOI: 10.1007/S00345-011-0772-2 | 0.403 | |||
| 2012 | Fairey AS, Kassouf W, Aprikian AG, Chin JL, Izawa JI, Fradet Y, Lacombe L, Rendon RA, Bell D, Cagiannos I, Drachenberg DE, Lattouf JB, Estey EP. Age ≥ 80 years is independently associated with survival outcomes after radical cystectomy: results from the Canadian Bladder Cancer Network Database. Urologic Oncology. 30: 825-32. PMID 21889368 DOI: 10.1016/J.Urolonc.2011.07.014 | 0.37 | |||
| 2012 | Fradet Y, Kubota Y, Schalken JA, Uchida T, Yoshida O. Genetic and molecular markers in the prognosis of bladder cancer. Urologic Oncology. 4: 139-44. PMID 21227219 DOI: 10.1016/S1078-1439(99)00021-6 | 0.397 | |||
| 2012 | Mauermann J, Fradet Y, Kassouf W, Rendon R, Jacobsen N, Fairey A, Izawa J, Kapoor A, Black P, Tanguay S, Chin J, So A, Lattouf JB, Bell D, Saad F, et al. 767 Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: A multicenter analysis of 742 patients European Urology Supplements. 11. DOI: 10.1016/S1569-9056(12)60764-7 | 0.417 | |||
| 2012 | Rink M, Ehdaie B, Cha EK, Hansen J, Svatek R, Chromecki TF, Fajkovic H, Novara G, Daneshmand S, Fradet Y, Lotan Y, Sagalowsky AI, Bastian PJ, Kassouf W, Fritsche HM, et al. 603 Clinical nodal staging scores for bladder cancer: A proposal for preoperative risk-assessment European Urology Supplements. 11. DOI: 10.1016/S1569-9056(12)60600-9 | 0.368 | |||
| 2012 | Morales E, Shariat S, Karakiewicz P, Volkmer B, Kassouf W, Fradet Y, Novara G, Fritsche H, Bastian P, Izawa J, Stief C, Ficarra V, Rink M, Lerner S, Schoenberg M, et al. 1906 Positive Surgical Margins Contribute To Delayed Failures In Patients Undergoing Radical Cystectomy For Bladder Cancer The Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.2062 | 0.4 | |||
| 2011 | Sargent DJ, Shi Q, Bot BM, Resnick MB, Meyers MO, Goldar-Najafi A, Clancy TE, Gill S, Siemons GO, Fradet Y. GCC expression in lymph nodes (LNs) as a significant determinant of recurrence in stage II colon cancer (CC) patients (pts). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 369. PMID 27985505 DOI: 10.1200/Jco.2011.29.4_Suppl.369 | 0.355 | |||
| 2011 | Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, Williamsen S, Hodge P, Meinke J, Blase A, Penabella Y, Day JR, Varambally R, Han B, Wood D, ... ... Fradet Y, et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Science Translational Medicine. 3: 94ra72. PMID 21813756 DOI: 10.1126/Scitranslmed.3001970 | 0.365 | |||
| 2011 | Nadeau G, Bellemare J, Audet-Walsh É, Flageole C, Huang SP, Bao BY, Douville P, Caron P, Fradet Y, Lacombe L, Guillemette C, Lévesque E. Deletions of the androgen-metabolizing UGT2B genes have an effect on circulating steroid levels and biochemical recurrence after radical prostatectomy in localized prostate cancer. The Journal of Clinical Endocrinology and Metabolism. 96: E1550-7. PMID 21733997 DOI: 10.1210/Jc.2011-1049 | 0.432 | |||
| 2011 | Audet-Walsh E, Bellemare J, Nadeau G, Lacombe L, Fradet Y, Fradet V, Huang SP, Bao BY, Douville P, Girard H, Guillemette C, Lévesque E. SRD5A polymorphisms and biochemical failure after radical prostatectomy. European Urology. 60: 1226-34. PMID 21715084 DOI: 10.1016/J.Eururo.2011.06.020 | 0.31 | |||
| 2011 | Nuhn P, Bastian PJ, Novara G, Svatek RS, Karakiewicz PI, Skinner E, Fradet Y, Izawa JI, Kassouf W, Montorsi F, Müller SC, Fritsche HM, Sonpavde G, Tilki D, Isbarn H, et al. Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery. Urologia Internationalis. 87: 42-8. PMID 21659717 DOI: 10.1159/000325463 | 0.389 | |||
| 2011 | Sargent DJ, Resnick MB, Meyers MO, Goldar-Najafi A, Clancy T, Gill S, Siemons GO, Shi Q, Bot BM, Wu TT, Beaudry G, Haince JF, Fradet Y. Evaluation of guanylyl cyclase C lymph node status for colon cancer staging and prognosis. Annals of Surgical Oncology. 18: 3261-70. PMID 21533822 DOI: 10.1245/S10434-011-1731-2 | 0.357 | |||
| 2011 | Chalasani V, Kassouf W, Chin JL, Fradet Y, Aprikian AG, Fairey AS, Estey E, Lacombe L, Rendon R, Bell D, Cagiannos I, Drachenberg D, Lattouf JB, Izawa JI. Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 5: 83-7. PMID 21470529 DOI: 10.5489/Cuaj.10040 | 0.329 | |||
| 2011 | Sonpavde G, Khan MM, Svatek RS, Lee R, Novara G, Tilki D, Lerner SP, Amiel GE, Skinner E, Karakiewicz PI, Bastian PJ, Kassouf W, Fritsche HM, Izawa JI, Scherr DS, ... ... Fradet Y, et al. Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. The Journal of Urology. 185: 1216-21. PMID 21334687 DOI: 10.1016/J.Juro.2010.11.082 | 0.413 | |||
| 2011 | Smith SC, Baras AS, Dancik G, Ru Y, Ding KF, Moskaluk CA, Fradet Y, Lehmann J, Stöckle M, Hartmann A, Lee JK, Theodorescu D. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. The Lancet. Oncology. 12: 137-43. PMID 21256081 DOI: 10.1016/S1470-2045(10)70296-5 | 0.412 | |||
| 2011 | Svatek RS, Shariat SF, Novara G, Skinner EC, Fradet Y, Bastian PJ, Kamat AM, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Tilki D, Ficarra V, Volkmer BG, Isbarn H, et al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. Bju International. 107: 898-904. PMID 21244604 DOI: 10.1111/J.1464-410X.2010.09628.X | 0.35 | |||
| 2011 | Sonpavde G, Khan MM, Lerner SP, Svatek RS, Novara G, Karakiewicz PI, Skinner E, Tilki D, Kassouf W, Fradet Y, Dinney CP, Fritsche HM, Izawa JI, Bastian PJ, Ficarra V, et al. Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. The Journal of Urology. 185: 456-61. PMID 21167527 DOI: 10.1016/J.Juro.2010.09.110 | 0.34 | |||
| 2011 | Aziz A, Lessard A, Moore K, Hovington H, Latulippe E, Larue H, Fradet Y, Lacombe L. Improved cancer specific-survival in patients with carcinoma invading bladder muscle expressing cyclo-oxygenase-2. Bju International. 108: 531-7. PMID 21166751 DOI: 10.1111/J.1464-410X.2010.09909.X | 0.395 | |||
| 2011 | Sonpavde G, Khan MM, Svatek RS, Lee R, Novara G, Tilki D, Lerner SP, Amiel GE, Skinner E, Karakiewicz PI, Bastian PJ, Kassouf W, Fritsche HM, Izawa JI, Ficarra V, ... ... Fradet Y, et al. Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. Bju International. 108: 687-92. PMID 21087453 DOI: 10.1111/J.1464-410X.2010.09902.X | 0.4 | |||
| 2011 | Fradet Y. Invasive bladder cancer: time is of the essence. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 2: 109. PMID 18542742 DOI: 10.5489/Cuaj.483 | 0.427 | |||
| 2011 | Tomlins SA, Aubin S, Siddiqui J, Lonigro R, Sefton-Miller L, Miick S, Williamsen S, Hodge P, Meinke J, Blase A, Penabella Y, Day J, Rhodes DR, Sakamoto K, Silberstein J, ... Fradet Y, et al. Abstract 2815: Urine TMPRSS2:ERG for prostate cancer risk stratification in men with elevated serum PSA Cancer Research. 71: 2815-2815. DOI: 10.1158/1538-7445.Am2011-2815 | 0.473 | |||
| 2011 | Fradet V, Lévesque J, Bergeron A, Lacombe L, Dujardin T, Tiguert R, Fradet Y. UP-02.184 Urinary PCA3 and Cancer Progression Under Active Surveillance of Prostate Cancer Urology. 78: S324. DOI: 10.1016/S1569-9056(13)60277-8 | 0.456 | |||
| 2011 | Auprich M, Haese A, De LTA, Van Poppel H, Marberger M, Abbou C, Stenzl A, Mulders P, Schalken J, Huland H, Stillebroer A, Van GP, Fradet Y, Marks L, Ellis W, et al. 641 CRITICAL ASSESSMENT OF URINARY PROSTATE CANCER GENE 3 (PCA3) IN THE PREDICTION OF AGGRESSIVE PROSTATE CANCER (GLEASON score ≥ 7) AT BIOPSY European Urology Supplements. 10: 207. DOI: 10.1016/S1569-9056(11)60630-1 | 0.332 | |||
| 2011 | Fradet V, Neveu B, Moreel X, Bergeron A, Larue H, Fradet Y. UP-02.084 Active Inflammatory State and Reactivity of Normal Prostate Epithelium and Aggressive Prostate Cancer Urology. 78: S288-S289. DOI: 10.1016/J.Urology.2011.07.902 | 0.401 | |||
| 2011 | Fradet V, Lodde M, Mauermann J, Caron A, Lacombe L, Dujardin T, Fradet Y. POD-07.07 Long-Term Cancer Outcomes After Radical Prostatectomy and Selective Salvage Radiotherapy in 1670 Pt2-3N0M0 Patients by Margins Status: Quantification of Overtreatment with Adjuvant Radiotherapy for all Positive Margins Urology. 78: S25. DOI: 10.1016/J.Urology.2011.07.457 | 0.386 | |||
| 2011 | Fradet Y, Ayari C, Bergeron A, LaRue H. 868 Toll-Like Receptor 3 As A Potential Therapeutic Target In Bladder Cancer The Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.692 | 0.335 | |||
| 2011 | Auprich M, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou C, Stillebroer AB, van Gils MP, Schalken JA, Fradet Y, Marks LS, de la Taille A, Ellis W, Partin AW, et al. 2320 INITIAL AND REPEAT PROSTATE BIOPSY: COMPARATIVE PERFORMANCE ANALYSIS OF PSA, %FPSA, PROSTATE VOLUME AND URINARY PCA3 INCLUDING DEVELOPMENT OF NOVEL PCA3 CUT-OFF THRESHOLDS Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.2567 | 0.373 | |||
| 2011 | Fradet Y, Audet-Walsh E, Bellemare J, Nadeau G, Lacombe L, Douville P, Girard H, Guillemette C, Lévesque E. 2288 Prognostic Impact Of Inherited Genetic Variations In Srd5A And Androgen Inactivating Ugt2B Genes In Prostate Cancer After Prostatectomy The Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.2533 | 0.418 | |||
| 2011 | Fitzgerald J, Shariat SF, Dinney CP, Novara G, Skinner EC, Fradet Y, Bastian PJ, Kassouf W, Karakiewicz PI, Fritsche H, Izawa JI, Tilki D, Ficarra V, Volkmer B, Isbarn H, et al. 1982 NODAL YIELD IS NOT INDEPENDENTLY ASSOCIATED WITH SURVIVAL IN PATIENTS WITHOUT NODAL METASTASIS AT RADICAL CYSTECTOMY Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.2208 | 0.346 | |||
| 2011 | Karl A, Eisenhut C, Grossman B, Stenzl A, Fradet Y, Mynderse L, Soloway M, Witjes A, Kriegmair M, Burger M. 1890 Histopathological Evaluation Of Bladder Cancer Is Reliable Even On An Intercontinental Scale: Comparison Of Local And Centrally Reviewed Histopathology For A Multicenter Intercontinental Trial The Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.2014 | 0.377 | |||
| 2011 | Auprich M, Haese A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou C, Stillebroer AB, van Gils MP, Schalken JA, Fradet Y, Marks LS, de la Taille A, Ellis W, et al. 987 CRITICAL ASSESSMENT OF URINARY PROSTATE CANCER GENE 3 (PCA3) IN THE PREDICTION OF AGGRESSIVE PROSTATE CANCER (GLEASON SCORE ≥ 7) AT BIOPSY Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.1019 | 0.441 | |||
| 2010 | Trudel D, Fradet Y, Meyer F, Têtu B. Matrix metalloproteinase 9 is associated with Gleason score in prostate cancer but not with prognosis. Human Pathology. 41: 1694-701. PMID 20825973 DOI: 10.1016/J.Humpath.2010.05.001 | 0.476 | |||
| 2010 | Svatek RS, Shariat SF, Lasky RE, Skinner EC, Novara G, Lerner SP, Fradet Y, Bastian PJ, Kassouf W, Karakiewicz PI, Fritsche HM, Müller SC, Izawa JI, Ficarra V, Sagalowsky AI, et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4461-7. PMID 20651056 DOI: 10.1158/1078-0432.Ccr-10-0457 | 0.387 | |||
| 2010 | Tilki D, Svatek RS, Novara G, Seitz M, Godoy G, Karakiewicz PI, Kassouf W, Fradet Y, Fritsche HM, Sonpavde G, Izawa JI, Ficarra V, Lerner SP, Schoenberg M, Stief CG, et al. Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. The Journal of Urology. 184: 888-94. PMID 20643448 DOI: 10.1016/J.Juro.2010.04.081 | 0.422 | |||
| 2010 | Tilki D, Svatek RS, Karakiewicz PI, Novara G, Seitz M, Sonpavde G, Gupta A, Kassouf W, Fradet Y, Ficarra V, Skinner E, Lotan Y, Sagalowsky AI, Stief CG, Reich O, et al. pT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder. The Journal of Urology. 184: 470-4. PMID 20620401 DOI: 10.1016/J.Juro.2010.04.007 | 0.394 | |||
| 2010 | Haince JF, Houde M, Beaudry G, L'espérance S, Garon G, Desaulniers M, Hafer LJ, Heald JI, Lyle S, Grossman SR, Têtu B, Sargent DJ, Fradet Y. Comparison of histopathology and RT-qPCR amplification of guanylyl cyclase C for detection of colon cancer metastases in lymph nodes. Journal of Clinical Pathology. 63: 530-7. PMID 20498026 DOI: 10.1136/Jcp.2009.072983 | 0.327 | |||
| 2010 | Robinson VL, Porter M, Messing E, Fradet Y, Kamat AM, Lotan Y. BCAN Think Tank session 2: Molecular detection of bladder cancer: the path to progress. Urologic Oncology. 28: 334-7. PMID 20439033 DOI: 10.1016/J.Urolonc.2009.07.026 | 0.396 | |||
| 2010 | Novara G, Svatek RS, Karakiewicz PI, Skinner E, Ficarra V, Fradet Y, Lotan Y, Isbarn H, Capitanio U, Bastian PJ, Kassouf W, Fritsche HM, Izawa JI, Tilki D, Dinney CP, et al. Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. The Journal of Urology. 183: 2165-70. PMID 20399473 DOI: 10.1016/J.Juro.2010.02.021 | 0.349 | |||
| 2010 | Lodde M, Lacombe L, Fradet Y. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer. Urology. 76: 1189-93. PMID 20303155 DOI: 10.1016/J.Urology.2009.12.057 | 0.429 | |||
| 2010 | Shariat SF, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U, Bastian PJ, Volkmer BG, Kassouf W, Novara G, Fritsche HM, Izawa JI, Ficarra V, Lerner SP, Sagalowsky AI, ... ... Fradet Y, et al. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. Bju International. 105: 1402-12. PMID 20132195 DOI: 10.1111/J.1464-410X.2010.09217.X | 0.421 | |||
| 2010 | Tilki D, Reich O, Karakiewicz PI, Novara G, Kassouf W, Ergün S, Fradet Y, Ficarra V, Sonpavde G, Stief CG, Skinner E, Svatek RS, Lotan Y, Sagalowsky AI, Shariat SF. Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. European Urology. 58: 112-7. PMID 20097469 DOI: 10.1016/J.Eururo.2010.01.015 | 0.352 | |||
| 2010 | Tilki D, Svatek RS, Karakiewicz PI, Isbarn H, Reich O, Kassouf W, Fradet Y, Novara G, Fritsche HM, Bastian PJ, Izawa JI, Stief CG, Ficarra V, Lerner SP, Schoenberg M, et al. Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. The Journal of Urology. 183: 87-93. PMID 19942232 DOI: 10.1016/J.Juro.2009.08.145 | 0.393 | |||
| 2010 | Shariat SF, Chade DC, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Montorsi F, Lerner SP, Sagalowsky AI, Cote RJ, Lotan Y. Combination of Multiple Molecular Markers Can Improve Prognostication in Patients With Locally Advanced and Lymph Node Positive Bladder Cancer Journal of Urology. 183: 68-75. PMID 19913255 DOI: 10.1016/J.Juro.2009.08.115 | 0.395 | |||
| 2010 | Shariat SF, Bolenz C, Karakiewicz PI, Fradet Y, Ashfaq R, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Rigaud J, Müller SC, Lerner SP, Montorsi F, Sagalowsky AI, Cote RJ, et al. p53 expression in patients with advanced urothelial cancer of the urinary bladder. Bju International. 105: 489-95. PMID 19659466 DOI: 10.1111/J.1464-410X.2009.08742.X | 0.42 | |||
| 2010 | Sonpavde G, Khan MM, Lerner SP, Svatek RS, Skinner EC, Karakiewicz PI, Kassouf W, Dinney CP, Fradet Y, Shariat SF. Correlation of disease-free survival at 2 to 3 years and 5-year overall survival in patients with muscle-invasive bladder cancer undergoing radical cystectomy. Journal of Clinical Oncology. 28: 4576-4576. DOI: 10.1200/Jco.2010.28.15_Suppl.4576 | 0.347 | |||
| 2010 | Smith SC, Baras AS, Ding K, Hartmann A, Fradet Y, Moskaluk C, Lee JK, Theodorescu D. Abstract LB-65: A gene expression predictor of pathological node stage of urothelial bladder cancer Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-65 | 0.373 | |||
| 2010 | Groskopf J, Aubin S, Tomlins S, Sakamoto K, Silberstein J, Siddiqui J, Penabella Y, Fradet Y, Rittenhouse H, Chinnaiyan A. 871 URINE MEASUREMENT OF TMPRSS2: ERG FOR THE EARLY DETECTION OF SIGNIFICANT PROSTATE CANCER European Urology Supplements. 9: 275-276. DOI: 10.1016/S1569-9056(10)60853-6 | 0.426 | |||
| 2010 | Shariat S, Svatek R, Tilki D, Skinner E, Karakiewicz P, Capitanio U, Bastian P, Volkmer B, Kassouf W, Novara G, Fritsche H, Izawa J, Ficarra V, Lerner S, Sagalowsky A, ... ... Fradet Y, et al. 323 INTERNATIONAL VALIDATION OF THE PROGNOSTIC VALUE OF LYMPHOVASCULAR INVASION IN RADICAL CYSTECTOMY PATIENTS European Urology Supplements. 9: 127. DOI: 10.1016/S1569-9056(10)60321-1 | 0.322 | |||
| 2010 | Svatek R, Shariat S, Skinner E, Novara G, Lerner S, Fradet Y, Bastian P, Kassouf W, Karakiewicz P, Fritsche H, Müller S, Izawa J, Ficarra V, Sagalowsky A, Schoenberg M, et al. 313 Adjuvant Chemotherapy For Urothelial Carcinoma Of The Urinary Bladder The Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.377 | 0.318 | |||
| 2010 | Nadeau G, Bellemare J, Douville P, Meyer F, Fradet Y, Guillemette C, Lacombe L, Lévesque E. 2122 Copy Number Variation Of Sex-Steroid Metabolizing Genes As Biomarkers Of Prostate Cancer Recurrence After Prostatectomy: Looking At The End Of The Androgenic Signal The Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.2210 | 0.411 | |||
| 2010 | Sakamoto K, Aubin S, Tomlins S, Kane C, Downs T, Silberstein J, Siddiqui J, Penabella Y, Fradet Y, Rittenhouse H, Groskopf J, Chinnaiyan A. 2121 Urine Measurement Of Tmprss2:Erg For The Early Detection Of Significant Prostate Cancer The Journal of Urology. 183: 275-276. DOI: 10.1016/J.Juro.2010.02.2209 | 0.426 | |||
| 2010 | Yafi FA, Aprikian AG, Fradet Y, Chin JL, Izawa J, Rendon R, Estey E, Fairey A, Cagiannos I, Lacombe L, Lattouf J, Bell D, Drachenberg D, Kassouf W. 1835 Risk-Stratified Surveillance Guidelines Following Radical Cystectomy For Bladder Cancer: The Canadian Bladder Cancer Network Experience The Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.1773 | 0.406 | |||
| 2010 | Power N, Bell D, Kassouf W, Aprikian AG, Fradet Y, Lacombe L, Chin J, Izawa J, Estey E, Fairey A, Cagiannos I, Lattouf J, Drachenberg D, Rendon RA. 1826 Outcomes For Patients With Pt3-4 Or Pn+ Bladder Cancer Treated With Radical Cystectomy: Canadian Bladder Cancer Network The Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.1764 | 0.423 | |||
| 2010 | Reich O, Tilki D, Svatek R, Karakiewicz P, Isbarn H, Kassouf W, Fradet Y, Novara G, Fritsche H, Bastian P, Izawa J, Ficarra V, Lerner S, Schoenberg M, Dinney C, et al. 1825 CLINICAL OUTCOME IN PATIENTS WITH PT4 UROTHELIAL CARCINOMA AT RADICAL CYSTECTOMY Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.1763 | 0.313 | |||
| 2010 | Sandhu G, Aprikian A, Chin J, Fradet Y, Izawa J, Estey E, Fairey A, Rendon R, Cagiannos I, Lacombe L, Lattouf J, Bell D, Kassouf W, Drachenberg D. 1709 ACHIEVING PT0N0 AT RADICAL CYSTECTOMY: OUTCOMES OF 135 PT0N0 BLADDER CANCER PATIENTS TREATED WITH RADICAL CYSTECTOMY: THE CANADIAN BLADDER CANCER NETWORK EXPERIENCE Journal of Urology. 183. DOI: 10.1016/j.juro.2010.02.1556 | 0.311 | |||
| 2010 | Shariat SF, Meryn S, Lee R, Ashfaq R, Karakiewicz PI, Fradet Y, Montorsi F, Bastian PJ, Nielsen ME, Lerner SP, Sagalowsky AI, Cote RJ, Lotan Y. The Combination of Multiple Cell Cycle Regulators Improves Prognosis in Patients with Pathologic Organ-Confined Bladder Cancer: A Multicenter External Validation Study Journal of Men's Health. 7: 342-342. DOI: 10.1016/J.Jomh.2010.09.193 | 0.392 | |||
| 2010 | Chun FK, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PFA, Huland H, Abbou CC, Stillebroer AB, van Gils MPMQ, Schalken JA, Fradet Y, Marks LS, Ellis W, Partin AW, et al. Reply to Juan Morote's Letter to the Editor re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. Eur Urol 2009;56:659-68 European Urology. 57: e2-e3. DOI: 10.1016/J.Eururo.2009.09.042 | 0.356 | |||
| 2009 | Fradet Y. Screening for bladder cancer: the best opportunity to reduce mortality. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 3: S180-3. PMID 20019981 DOI: 10.5489/Cuaj.1192 | 0.41 | |||
| 2009 | Fradet Y. Arguments against investing widely in robotic prostatectomy in Canada: a wrong focus on tool box rather than surgical expertise. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 3: 486-7. PMID 20019979 DOI: 10.5489/Cuaj.1181 | 0.336 | |||
| 2009 | Shariat SF, Karakiewicz PI, Godoy G, Karam JA, Ashfaq R, Fradet Y, Isbarn H, Montorsi F, Jeldres C, Bastian PJ, Nielsen ME, Müller SC, Sagalowsky AI, Lotan Y. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 7012-9. PMID 19903782 DOI: 10.1158/1078-0432.Ccr-08-2554 | 0.409 | |||
| 2009 | Shariat SF, Lotan Y, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Montorsi F, Müller SC, Karam JA, Heukamp LC, Netto G, et al. p53 predictive value for pT1-2 N0 disease at radical cystectomy. The Journal of Urology. 182: 907-13. PMID 19616250 DOI: 10.1016/J.Juro.2009.05.024 | 0.317 | |||
| 2009 | Bolduc S, Inman BA, Lacombe L, Fradet Y, Tremblay RR. Early detection of prostate cancer local recurrence by urinary prostate-specific antigen. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 3: 213-7. PMID 19543465 DOI: 10.5489/Cuaj.1074 | 0.434 | |||
| 2009 | Klotz L, Drachenberg D, Fradet Y, Saad F, Trachtenberg J, Zlotta A. Gleason grading controversies: what the chemoprevention trials have taught us. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 3: S115-20. PMID 19543430 DOI: 10.5489/Cuaj.1115 | 0.463 | |||
| 2009 | Fradet Y, Klotz L, Trachtenberg J, Zlotta A. The burden of prostate cancer in Canada. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 3: S92-S100. PMID 19543427 DOI: 10.5489/Cuaj.1113 | 0.449 | |||
| 2009 | Bergeron A, Picard V, LaRue H, Harel F, Hovington H, Lacombe L, Fradet Y. High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer. International Journal of Cancer. Journal International Du Cancer. 125: 1365-71. PMID 19533752 DOI: 10.1002/Ijc.24503 | 0.363 | |||
| 2009 | Shariat SF, Bolenz C, Godoy G, Fradet Y, Ashfaq R, Karakiewicz PI, Isbarn H, Jeldres C, Rigaud J, Sagalowsky AI, Lotan Y. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. The Journal of Urology. 182: 78-84; discussion 84. PMID 19447418 DOI: 10.1016/J.Juro.2009.02.125 | 0.365 | |||
| 2009 | Inman BA, Tran VT, Fradet Y, Lacombe L. Carcinoma of the upper urinary tract: predictors of survival and competing causes of mortality. Cancer. 115: 2853-62. PMID 19434668 DOI: 10.1002/Cncr.24339 | 0.393 | |||
| 2009 | Fradet Y. Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen. Current Opinion in Urology. 19: 243-6. PMID 19325493 DOI: 10.1097/Mou.0B013E32832A08B5 | 0.418 | |||
| 2009 | Chun FK, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Stillebroer AB, van Gils MP, Schalken JA, Fradet Y, Marks LS, Ellis W, Partin AW, et al. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. European Urology. 56: 659-67. PMID 19304372 DOI: 10.1016/j.eururo.2009.03.029 | 0.333 | |||
| 2009 | Ayari C, LaRue H, Hovington H, Decobert M, Harel F, Bergeron A, Têtu B, Lacombe L, Fradet Y. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy. European Urology. 55: 1386-95. PMID 19193487 DOI: 10.1016/J.Eururo.2009.01.040 | 0.312 | |||
| 2009 | Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U, Montorsi F, Bastian PJ, Nielsen ME, Müller SC, Rigaud J, Heukamp LC, Netto G, Lerner SP, Sagalowsky AI, et al. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. Journal of the National Cancer Institute. 101: 114-9. PMID 19141773 DOI: 10.1093/jnci/djn451 | 0.342 | |||
| 2009 | Lodde M, Levesque J, Lacombe L, Dujardin T, Tiguert R, Fradet Y. 844 PHASE II STUDY OF TREATMENT WITH 5-ALPHA REDUCTASE INHIBITORS (5ARIS) IN LOW RISK PROSTATE CANCER European Urology Supplements. 8: 331. DOI: 10.1016/S1569-9056(09)60832-0 | 0.371 | |||
| 2009 | Lodde M, Lacombe L, Harel F, Wood D, Harris M, Fradet Y. 515 EXTENT OF LYMPHADENECTOMY AND BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY: A MULTICENTER STUDY European Urology Supplements. 8: 249. DOI: 10.1016/S1569-9056(09)60511-X | 0.338 | |||
| 2009 | Silberstein J, Aubin SMj, Weber A, Christensen K, Kashefi C, Fradet Y, Sakamoto K. URINE ASSAYS FOR PCA3 AND TMPRSS2:ERG GENE FUSION TO PREDICT THE DIAGNOSIS OF PROSTATE CANCER Journal of Urology. 181: 813-813. DOI: 10.1016/S0022-5347(09)62266-7 | 0.417 | |||
| 2009 | Mynderse L, Stenzl A, Denzinger S, Fradet Y, Soloway MS, Karl A, Kriegmair M, Witjes A, Grossman HB. Hexaminolevulinate Fluorescence Cystoscopy Improves Detection And Resection Of Papillary Bladder Cancer Lesions And Reduces Early Recurrences The Journal of Urology. 181: 689-689. DOI: 10.1016/S0022-5347(09)61931-5 | 0.337 | |||
| 2009 | Shariat SF, Karakiewicz PI, Fradet Y, Ashfaq R, Bolenz C, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Groshen S, Rigaud J, Müller SC, Lerner SP, Montorsi F, Sagalowsky AI, et al. IMPROVED PREDICTION OF CLINICAL OUTCOMES IN PATIENTS WITH ADVANCED BLADDER CANCER USING A PANEL OF FOUR CELL CYCLE REGULATORS The Journal of Urology. 181: 628. DOI: 10.1016/S0022-5347(09)61764-X | 0.383 | |||
| 2009 | Yafi FA, Aprikian AG, Fradet Y, Izawa JI, Chin JL, Estey EP, Chetner MP, Cagiannos I, Lacombe L, Lattouf J, Rendon RA, Bell D, Drachenberg D, Kassouf W. CONTEMPORARY OUTCOMES OF RADICAL CYSTECTOMY IN 2287 PATIENTS WITH TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A CANADIAN MULTI-INSTITUTIONAL EXPERIENCE Journal of Urology. 181: 377-377. DOI: 10.1016/S0022-5347(09)61065-X | 0.325 | |||
| 2009 | Aziz A, Moore K, Blackburn F, Lessard A, Hovington H, Harel F, Larue H, Fradet Y, Lacombe L. Improved Cancer Specific-Survival In Patients With Muscle-Invasive Bladder Cancer Expressing Cyclo-Oxygenase-2 The Journal of Urology. 181: 69-69. DOI: 10.1016/S0022-5347(09)60202-0 | 0.431 | |||
| 2009 | Yafi F, Aprikian A, Chin J, Fradet Y, Izawa J, Estey E, Fairey A, Rendon R, Cagiannos I, Lacombe L, Lattouf J, Bell D, Drachenberg D, Kassouf W. POD-07.10: Outcome Analysis of Bladder Cancer Patients Treated with Radical Cystectomy in a Universal Health Care System: A Multicenter Canadian Series of 2,287 Patients Urology. 74: S23-S24. DOI: 10.1016/J.Urology.2009.07.1149 | 0.376 | |||
| 2009 | Chalasani V, Martinez C, Izawa J, Aprikian A, Fradet Y, Estey E, Fairey A, Rendon R, Cagiannos I, Lacombe L, Lattouf J, Bell D, Drachenberg D, Kassouf W, Chin J. POD-07.09: Incidental Adenocarcinoma of the Prostate Discovered at the Time of Radical Cystectomy: Analysis of the Canadian Bladder Cancer Network Database Urology. 74: S23. DOI: 10.1016/J.Urology.2009.07.1148 | 0.437 | |||
| 2008 | Lodde M, Fradet Y. The detection of genetic markers of bladder cancer in urine and serum. Current Opinion in Urology. 18: 499-503. PMID 18670274 DOI: 10.1097/Mou.0B013E32830B86D1 | 0.305 | |||
| 2008 | Decobert M, LaRue H, Harel F, Meyer F, Fradet Y, Lacombe L. Maintenance bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancer: how much is enough? Cancer. 113: 710-6. PMID 18543328 DOI: 10.1002/Cncr.23627 | 0.414 | |||
| 2008 | Fradet Y. The management of high-risk prostate cancer in 2008. World Journal of Urology. 26: 203. PMID 18458914 DOI: 10.1007/S00345-008-0261-4 | 0.409 | |||
| 2008 | Lodde M, Harel F, Lacombe L, Fradet Y. Substratification of high-risk localised prostate cancer treated by radical prostatectomy. World Journal of Urology. 26: 225-9. PMID 18369635 DOI: 10.1007/S00345-008-0252-5 | 0.438 | |||
| 2008 | Trudel D, Fradet Y, Meyer F, Harel F, Têtu B. Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry. Human Pathology. 39: 731-9. PMID 18329693 DOI: 10.1016/J.Humpath.2007.09.021 | 0.322 | |||
| 2008 | Hadaschik BA, Adomat H, Fazli L, Fradet Y, Andersen RJ, Gleave ME, So AI. Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 1510-8. PMID 18316576 DOI: 10.1158/1078-0432.Ccr-07-4475 | 0.373 | |||
| 2008 | Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, Ellis WJ, Marks LS, Fradet Y, Rittenhouse H, Groskopf J. PCA3: a molecular urine assay for predicting prostate biopsy outcome. The Journal of Urology. 179: 1587-92. PMID 18295257 DOI: 10.1016/j.juro.2007.11.038 | 0.3 | |||
| 2008 | Patry G, Hovington H, Larue H, Harel F, Fradet Y, Lacombe L. Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer. International Journal of Cancer. 122: 1592-7. PMID 18058798 DOI: 10.1002/Ijc.23240 | 0.468 | |||
| 2008 | Fradet Y, Lodde M, Tiguert R, Lebel M, Chautard D, Harel F, Lacombe L. TREATMENT OUTCOME OF IMMEDIATE VERSUS DELAYED HORMONE THERAPY IN PATIENTS WITH LYMPH NODE METASTASES FOLLOWING RADICAL PROSTATECTOMY European Urology Supplements. 7: 104. DOI: 10.1016/S1569-9056(08)60136-0 | 0.31 | |||
| 2008 | Shariat SF, Karakiewicz PI, Fradet Y, Ashfaq R, Stein JP, Bastian PJ, Nielsen ME, Suardi N, Montorsi F, Groshen S, Muller SC, Rigaud J, Heukamp LC, Netto GJ, Lerner SP, et al. Combination Of Cell Cycle Regulating Bio-Markers Improves Prognosis In Patients With Organ Confined Urothelial Cancer At Radical Cystectomy The Journal of Urology. 72: 578-578. DOI: 10.1016/S0022-5347(08)61698-5 | 0.406 | |||
| 2008 | Lodde M, Hovington H, Harel F, Harris MJ, Wood DP, Hugues Lebel M, Lacombe L, Fradet Y. IMPACT OF PELVIC LYMPHADENECTOMY ON DISEASE- FREE SURVIVAL AFTER RADICAL PROSTATECTOMY: A MULTICENTER STUDY Journal of Urology. 179: 193-193. DOI: 10.1016/S0022-5347(08)60560-1 | 0.308 | |||
| 2007 | Bolduc S, Lacombe L, Naud A, Grégoire M, Fradet Y, Tremblay RR. Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 1: 377-81. PMID 18542821 DOI: 10.5489/Cuaj.444 | 0.422 | |||
| 2007 | Schmitz-Dräger BJ, Fradet Y, Grossman HB. Bladder cancer markers in patient management: the current perspective. World Journal of Urology. 26: 1-3. PMID 18060549 DOI: 10.1007/S00345-007-0225-0 | 0.379 | |||
| 2007 | Popa I, Fradet Y, Beaudry G, Hovington H, Beaudry G, Têtu B. Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 20: 1121-7. PMID 17873893 DOI: 10.1038/Modpathol.3800963 | 0.43 | |||
| 2007 | Fradet Y, Grossman HB, Gomella L, Lerner S, Cookson M, Albala D, Droller MJ. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. The Journal of Urology. 178: 68-73; discussion 73. PMID 17499291 DOI: 10.1016/J.Juro.2007.03.028 | 0.305 | |||
| 2007 | Grossman HB, Gomella L, Fradet Y, Morales A, Presti J, Ritenour C, Nseyo U, Droller MJ. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. The Journal of Urology. 178: 62-7. PMID 17499283 DOI: 10.1016/J.Juro.2007.03.034 | 0.324 | |||
| 2007 | Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H, Groskopf J. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology. 69: 532-5. PMID 17382159 DOI: 10.1016/j.urology.2006.12.014 | 0.309 | |||
| 2007 | Fradet Y, Egerdie B, Andersen M, Tammela T, Nachabe M, Armstrong J, Morris T, Navani S. 24 TAMOXIFEN AS PROPHYLAXIS FOR PREVENTION OF GYNAECOMASTIA AND BREAST PAIN ASSOCIATED WITH BICALUTAMIDE 150 MG MONOTHERAPY IN PATIENTS WITH PROSTATE CANCER European Urology Supplements. 6: 28. DOI: 10.1016/S1569-9056(07)60024-4 | 0.373 | |||
| 2006 | Meyer F, Têtu B, Bairati I, Lacombe L, Fradet Y. Prostatic intraepithelial neoplasia in TURP specimens and subsequent prostate cancer. The Canadian Journal of Urology. 13: 3255-60. PMID 17076947 | 0.302 | |||
| 2006 | Fradet Y, Picard V, Bergeron A, LaRue H. Cancer-testis antigen expression in bladder cancer. Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie. 16: 421-8. PMID 17069033 | 0.316 | |||
| 2006 | Decobert M, Larue H, Bergeron A, Harel F, Pfister C, Rousseau F, Lacombe L, Fradet Y. Polymorphisms of the human NRAMP1 gene are associated with response to bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. The Journal of Urology. 175: 1506-11. PMID 16516037 DOI: 10.1016/S0022-5347(05)00653-1 | 0.393 | |||
| 2006 | Hervouet S, Savard J, Simard S, Ivers H, Laverdière J, Vigneault E, Fradet Y, Lacombe L. Psychological functioning associated with prostate cancer: cross-sectional comparison of patients treated with radiotherapy, brachytherapy, or surgery. Journal of Pain and Symptom Management. 30: 474-84. PMID 16310621 DOI: 10.1016/J.Jpainsymman.2005.05.011 | 0.34 | |||
| 2006 | Tiguert R, Lacombe L, Harrel F, Fradet Y. 972: Disease Outcome of Patients with A PSA ≥20 Treated by Radical Prostatectomy: Analysis of 177 Patients Journal of Urology. 175: 313-314. DOI: 10.1016/S0022-5347(18)33197-5 | 0.347 | |||
| 2006 | Pouliot F, Larue H, Girard J, Hovington H, Fradet Y. 612: Alterations of the Sonic Hedgehog Pathway in Human Superficial Bladder Cancer: Loss of PTC and GLI Expression Journal of Urology. 175: 197-198. DOI: 10.1016/S0022-5347(18)32858-1 | 0.373 | |||
| 2006 | Fradet Y, Groskopf J, Walker S, Deras I, Brentano S, Dujardin T, Audet J, Bodrug S, Blase A, Desaulniers M, Rittenhouse HG. 538: Protoype Aptima® PCA3 Molecular Urine Test: Development of a Method to Aid in the Diagnosis of Prostate Cancer The Journal of Urology. 175: 174-175. DOI: 10.1016/S0022-5347(18)32784-8 | 0.412 | |||
| 2005 | Habuchi T, Marberger M, Droller MJ, Hemstreet GP, Grossman HB, Schalken JA, Schmitz-Dräger BJ, Murphy WM, Bono AV, Goebell P, Getzenberg RH, Hautmann SH, Messing E, Fradet Y, Lokeshwar VB. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology. 66: 64-74. PMID 16399416 DOI: 10.1016/J.Urology.2005.08.065 | 0.443 | |||
| 2005 | Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP, Bono AV, Getzenberg RH, Goebell P, Schmitz-Dräger BJ, Schalken JA, Fradet Y, Marberger M, Messing E, Droller MJ. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology. 66: 35-63. PMID 16399415 DOI: 10.1016/J.Urology.2005.08.064 | 0.322 | |||
| 2005 | Inman BA, Harel F, Audet JF, Meyer F, Douville P, Fradet Y, Lacombe L. Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival. European Urology. 47: 695-702. PMID 15826765 DOI: 10.1016/J.Eururo.2004.12.015 | 0.403 | |||
| 2005 | Têtu B, Tiguert R, Harel F, Fradet Y. ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 18: 83-9. PMID 15389253 DOI: 10.1038/Modpathol.3800262 | 0.35 | |||
| 2005 | Savard J, Simard S, Hervouet S, Ivers H, Lacombe L, Fradet Y. Insomnia in men treated with radical prostatectomy for prostate cancer. Psycho-Oncology. 14: 147-56. PMID 15386779 DOI: 10.1002/Pon.830 | 0.395 | |||
| 2005 | Giachetti C, Groskopf J, Walker S, Deras I, Clark C, Bodrug S, Blase A, Brentano S, Rittenhouse H, Desaulniers M, Chypre C, Fradet Y. APTIMA® PCA3 Molecular Urine Test: Development of a Method to Aid in the Diagnosis of Prostate Cancer Urology. 66: 3-4. DOI: 10.1016/S1569-9056(06)61015-4 | 0.412 | |||
| 2005 | Moore K, Blackburn F, Hovington H, Harel F, Larue H, Lacombe L, Fradet Y. 919: Expression of Cyclooxygenase-2 is Associated with Stage, Grade and Recurrence-Free Survival in Superficial Bladder Cancer The Journal of Urology. 173: 248-248. DOI: 10.1016/S0022-5347(18)35075-4 | 0.414 | |||
| 2005 | Patry G, Hovington H, Larue H, Harel F, Fradet Y, Lacombe L. 612: Tissue Factor Expression as a Prognosis Factor in Patients with Muscle-Invasive Bladder Cancer Treated by Radical Cystectomy The Journal of Urology. 173: 167-167. DOI: 10.1016/S0022-5347(18)34852-3 | 0.382 | |||
| 2004 | Fradet Y, Saad F, Aprikian A, Dessureault J, Elhilali M, Trudel C, Mâsse B, Piché L, Chypre C. uPM3, a new molecular urine test for the detection of prostate cancer. Urology. 64: 311-5; discussion 31. PMID 15302485 DOI: 10.1016/J.Urology.2004.03.052 | 0.317 | |||
| 2004 | Tiguert R, Rigaud J, Fradet Y. Safety and outcome of early catheter removal after radical retropubic prostatectomy. Urology. 63: 513-7. PMID 15028448 DOI: 10.1016/J.Urology.2003.10.042 | 0.312 | |||
| 2004 | Hamed S, LaRue H, Hovington H, Girard J, Jeannotte L, Latulippe E, Fradet Y. Accelerated induction of bladder cancer in patched heterozygous mutant mice. Cancer Research. 64: 1938-42. PMID 15026327 DOI: 10.1158/0008-5472.Can-03-2031 | 0.349 | |||
| 2004 | Fradet Y. Bicalutamide (Casodex) in the treatment of prostate cancer. Expert Review of Anticancer Therapy. 4: 37-48. PMID 14748655 DOI: 10.1586/14737140.4.1.37 | 0.432 | |||
| 2004 | Rigaud J, Tiguert R, Decobert M, Hovington H, Latulippe E, Laverdiere J, Larue H, Lacombe L, Fradet Y. Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy. The Prostate. 58: 269-76. PMID 14743466 DOI: 10.1002/Pros.10329 | 0.434 | |||
| 2004 | Evans AJ, Gallie BL, Jewett MAS, Pond GR, Vandezande K, Underwood J, Fradet Y, Lim G, Marrano P, Zielenska M, Squire JA. Defining a 0.5-Mb Region of Genomic Gain on Chromosome 6p22 in Bladder Cancer by Quantitative-Multiplex Polymerase Chain Reaction American Journal of Pathology. 164: 285-293. PMID 14695341 DOI: 10.1016/S0002-9440(10)63118-5 | 0.312 | |||
| 2004 | Grossman HB, Gomella LG, Fradet Y, Presti JC, Ritenour CWM, Lerner SP, Cookson MS, Nseyo UO, Bihrle R, Fuchs GJ, Schoenberg MP, Droller MJ, Cure P. 263: The Use of Hexvix and Fluorescence Cystoscopy as an Adjunct in the Diagnosis of Stage TA/T1 Urothelial Cancer in the Urinary Bladder The Journal of Urology. 171: 69-69. DOI: 10.1016/S0022-5347(18)37525-6 | 0.345 | |||
| 2004 | Inman BA, Tran V, Meyer F, Fradet Y, Locombe L. 255: Risk Factors for Bladder Cancer Recurrence Following Urothelial Carcinoma of the Upper Urinary Tract The Journal of Urology. 171: 67-67. DOI: 10.1016/S0022-5347(18)37517-7 | 0.398 | |||
| 2003 | Trudel D, Fradet Y, Meyer F, Harel F, Têtu B. Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. Cancer Research. 63: 8511-5. PMID 14679018 | 0.301 | |||
| 2003 | Tiguert R, Rigaud J, Lacombe L, Laverdière J, Fradet Y. Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level. The Journal of Urology. 170: 447-50. PMID 12853796 DOI: 10.1097/01.Ju.0000075351.51838.B3 | 0.363 | |||
| 2003 | Rigaud J, Tiguert R, Fradet Y, Bouchot O. [Salvage radical prostatectomy after radiotherapy failure in localized prostatic cancer]. Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie. 12: 1179-87. PMID 12545622 | 0.326 | |||
| 2003 | Fradet Y. Role of radical prostatectomy in high-risk prostate cancer. The Canadian Journal of Urology. 8-13. PMID 12121588 | 0.359 | |||
| 2003 | Rigaud J, Tiguert R, Lacombe L, Fradet Y. Incidence, histology and follow-up of unsuspected prostatic cancer in patients undergoing radical cystoprostatectomy for bladder cancer European Urology Supplements. 2: 132. DOI: 10.1016/S1569-9056(03)80522-5 | 0.487 | |||
| 2003 | Aprikian A, Saad F, Dessureault J, Elhilali M, Trudel C, Piche L, Chypre C, Fradet Y. Multicenter study of the UPM3 test, a new molecular urine assay to detect prostate cancer European Urology Supplements. 2: 130. DOI: 10.1016/S1569-9056(03)80515-8 | 0.412 | |||
| 2003 | Rigaud J, Hovington H, Latulippe F, Lessard A, Larue L, Lacombe L, Fradet Y. Tissue-arrays of invasive bladder cancer: Validation of the technique and prognostic value of cyclin E, P53, P21 and P27 by immunohistochemical analysis European Urology Supplements. 2: 68. DOI: 10.1016/S1569-9056(03)80268-3 | 0.318 | |||
| 2002 | Champetier S, Fradet Y, Bachvarov D. Identification of two genes differentially expressed upon different spatial configuration of the MGH-U3 human bladder cancer cells. Urologic Oncology. 7: 57-61. PMID 12474523 DOI: 10.1016/S1078-1439(01)00130-2 | 0.753 | |||
| 2002 | Tiguert R, Lessard A, So A, Fradet Y. Prognostic markers in muscle invasive bladder cancer. World Journal of Urology. 20: 190-5. PMID 12196903 DOI: 10.1007/S00345-002-0279-Y | 0.39 | |||
| 2002 | Tiguert R, Fradet Y. New diagnostic and prognostic tools in bladder cancer. Current Opinion in Urology. 12: 239-43. PMID 11953681 DOI: 10.1097/00042307-200205000-00011 | 0.399 | |||
| 2001 | Meyer F, Bairati I, Bédard C, Lacombe L, Têtu B, Fradet Y. Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer. Urology. 58: 71-7. PMID 11502453 DOI: 10.1016/S0090-4295(01)01245-6 | 0.422 | |||
| 2001 | Lacombe L, Maillette A, Meyer F, Veilleux C, Moore L, Fradet Y. Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy. International Journal of Cancer. 95: 135-9. PMID 11307144 DOI: 10.1097/00005392-199904010-00951 | 0.475 | |||
| 2001 | Simoneau M, LaRue H, Aboulkassim TO, Meyer F, Moore L, Fradet Y. Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest. Oncogene. 19: 6317-23. PMID 11175346 DOI: 10.1038/Sj.Onc.1204022 | 0.327 | |||
| 2001 | Schmitz-Dräger BJ, Goebell PJ, Ebert T, Fradet Y. p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? European Urology. 38: 691-9;discussion 700. PMID 11111186 DOI: 10.1159/000020364 | 0.417 | |||
| 2001 | Bairati I, Larouche R, Meyer F, Moore L, Fradet Y. Lifetime occupational physical activity and incidental prostate cancer (Canada). Cancer Causes & Control : Ccc. 11: 759-64. PMID 11065013 DOI: 10.1023/A:1008936826337 | 0.423 | |||
| 2001 | Fradet Y, Lacombe L. Can biological markers predict recurrence and progression of superficial bladder cancer? Current Opinion in Urology. 10: 441-5. PMID 11005449 DOI: 10.1097/00042307-200009000-00013 | 0.389 | |||
| 2000 | Elhilali MM, Gleave M, Fradet Y, Davis I, Venner P, Saad F, Klotz L, Moore R, Ernst S, Paton V. Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma. The Canadian Urologic Oncology Group. Bju International. 86: 613-8. PMID 11069364 DOI: 10.1046/J.1464-410X.2000.00880.X | 0.311 | |||
| 2000 | Meyer F, Moore L, Bairati I, Lacombe L, Têtu B, Fradet Y. Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure. The Journal of Urology. 162: 2024-8. PMID 10569561 DOI: 10.1016/S0022-5347(05)68092-5 | 0.406 | |||
| 1999 | Pfister C, Lacombe L, Vezina MC, Moore L, Larue H, Têtu B, Meyer F, Fradet Y. Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumors. Human Pathology. 30: 1350-5. PMID 10571516 DOI: 10.1016/S0046-8177(99)90067-9 | 0.332 | |||
| 1999 | Meyer F, Bairati I, Shadmani R, Fradet Y, Moore L. Dietary fat and prostate cancer survival. Cancer Causes & Control : Ccc. 10: 245-51. PMID 10482482 DOI: 10.1023/A:1008913307947 | 0.444 | |||
| 1999 | Fradet Y, Meyer F, Bairati I, Shadmani R, Moore L. Dietary fat and prostate cancer progression and survival. European Urology. 35: 388-91. PMID 10325493 DOI: 10.1159/000019913 | 0.339 | |||
| 1999 | Klotz LH, Goldenberg SL, Jewett M, Barkin J, Chetner M, Fradet Y, Chin J, Laplante S. CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results Urology. 53: 757-763. PMID 10197852 DOI: 10.1016/S0090-4295(98)00616-5 | 0.428 | |||
| 1999 | Ekman P, Fradet Y, Meyer F, Bairati I, Shadmani R, Moore L, Peehl DM, Moul JW, Klocker H, Culig Z, Eder IE, Nessler-Menardi C, Hobisch A, Putz T, Bartsch G, et al. Prostatitis and Urethritis European Urology. 35: 557-566. DOI: 10.1159/000019902 | 0.361 | |||
| 1999 | Lianes P, Charytonowicz E, Cordon-Cardo C, Fradet Y, Grossman H, Hemstreet G, Waldman F, Chew K, Wheeless L, Faraggi D. Biomarker Study of Primary Nonmetastatic Versus Metastatic Invasive Bladder Cancer Journal of Urology. 161: 1716-1717. DOI: 10.1097/00005392-199905000-00100 | 0.311 | |||
| 1999 | Kattan MW, Witte M, Morton RA, Cangiano T, deKernion J, Eastham JA, Meyer F, Fradet Y. Validation Of A Nomogram For Predicting Disease Recurrence Following Radical Prostatectomy For Clinically Localized Prostate Cancer The Journal of Urology. 329. DOI: 10.1097/00005392-199904020-00319 | 0.445 | |||
| 1999 | JEWETT MA, VALIQUETTE L, SAMPSON HA, KATZ J, FRADET Y, REDELMEIER DA. ELECTROMOTIVE DRUG ADMINISTRATION OF LIDOCAINE AS AN ALTERNATIVE ANESTHESIA FOR TRANSURETHRAL SURGERY Journal of Urology. 161: 482-485. DOI: 10.1016/S0022-5347(01)61929-3 | 0.351 | |||
| 1999 | MEYER F, MOORE L, BAIRATI I, FRADET Y. DOWNWARD TREND IN PROSTATE CANCER MORTALITY IN QUEBEC AND CANADA Journal of Urology. 161: 1189-1191. DOI: 10.1016/S0022-5347(01)61628-8 | 0.411 | |||
| 1998 | Debruyne FJ, Murray R, Fradet Y, Johansson JE, Tyrrell C, Boccardo F, Denis L, Marberger JM, Brune D, Rassweiler J, Vangeneugden T, Bruynseels J, Janssens M, De Porre P. Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group. Urology. 52: 72-81. PMID 9671874 DOI: 10.1016/S0090-4295(98)00129-0 | 0.437 | |||
| 1998 | Fradet Y. Phenotypic characterization of bladder cancer. European Urology. 5-6. PMID 9615196 DOI: 10.1159/000052250 | 0.405 | |||
| 1998 | Meyer F, Bairati I, Fradet Y, Moore L. Dietary energy and nutrients in relation to preclinical prostate cancer. Nutrition and Cancer. 29: 120-6. PMID 9427974 DOI: 10.1080/01635589709514612 | 0.437 | |||
| 1998 | BAIRATI I, MEYER F, FRADET Y, MOORE L. DIETARY FAT AND ADVANCED PROSTATE CANCER Journal of Urology. 159: 1271-1275. DOI: 10.1016/S0022-5347(01)63579-1 | 0.454 | |||
| 1997 | LaRue H, Parent-Vaugeois C, Bergeron A, Champetier S, Fradet Y. Influence of spatial configuration on the expression of carcinoembryonic antigen and mucin antigens in human bladder cancer. International Journal of Cancer. 71: 986-92. PMID 9185702 DOI: 10.1002/(Sici)1097-0215(19970611)71:6<986::Aid-Ijc14>3.0.Co;2-4 | 0.787 | |||
| 1997 | Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M, Tetu B, Fradet Y, Bélanger A, Candas B. Neoadjuvant hormonal therapy: the Canadian experience. Urology. 49: 56-64. PMID 9123738 DOI: 10.1016/S0090-4295(97)00170-2 | 0.437 | |||
| 1997 | Grégoire M, Fradet Y, Meyer F, Têtu B, Bois R, Bédard G, Charrois R, Naud A. Diagnostic accuracy of urinary cytology, and deoxyribonucleic acid flow cytometry and cytology on bladder washings during followup for bladder tumors. The Journal of Urology. 157: 1660-4. PMID 9112500 DOI: 10.1016/S0022-5347(01)64827-4 | 0.331 | |||
| 1996 | Fradet Y. The role of neoadjuvant androgen deprivation prior to radical prostatectomy. The Urologic Clinics of North America. 23: 575-85. PMID 8948412 DOI: 10.1016/S0094-0143(05)70337-2 | 0.446 | |||
| 1996 | Têtu B, Allard P, Fradet Y, Roberge N, Bernard P. Prognostic significance of nuclear DNA content and S-phase fraction by flow cytometry in primary papillary superficial bladder cancer. Human Pathology. 27: 922-6. PMID 8816887 DOI: 10.1016/S0046-8177(96)90219-1 | 0.376 | |||
| 1996 | Bostwick DG, Wheeler TM, Blute M, Barrett DM, MacLennan GT, Sebo TJ, Scardino PT, Humphrey PA, Hudson MA, Fradet Y, Miller GJ, Crawford ED, Blumenstein BA, Mahran HE, Miles BJ. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies Urology. 48: 47-57. PMID 8693651 DOI: 10.1016/S0090-4295(96)00149-5 | 0.412 | |||
| 1996 | Bergeron A, Champetier S, LaRue H, Fradet Y. MAUB is a new mucin antigen associated with bladder cancer. The Journal of Biological Chemistry. 271: 6933-40. PMID 8636121 DOI: 10.1074/Jbc.271.12.6933 | 0.78 | |||
| 1996 | Elhilali MM, Ramsey EW, Barkin J, Casey RW, Boake RC, Beland G, Fradet Y, Trachtenberg J, Orovan WL, Schick E, Klotz LH. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Urology. 47: 335-42. PMID 8633398 DOI: 10.1016/S0090-4295(99)80449-X | 0.317 | |||
| 1996 | Van der Kwast TH, Têtu B, Fradet Y, Dupont A, Gomez J, Cusan L, Diamond P, Labrie F. Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy. The Prostate. 28: 227-31. PMID 8602398 DOI: 10.1002/(Sici)1097-0045(199604)28:4<227::Aid-Pros3>3.0.Co;2-A | 0.417 | |||
| 1996 | Vailancourt L, Ttu B, Fradet Y, Dupont A, Gomez J, Cusan L, Suburu ER, Diamond P, Candas B, Labrie F. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. The American Journal of Surgical Pathology. 20: 86-93. PMID 8540613 DOI: 10.1097/00000478-199601000-00010 | 0.44 | |||
| 1996 | Tetu B, Fradet Y, Allard P, Veilleux C, Roberge N, Bernard P. Prevalence and Clinical Significance of Her-2/neu, p53 and Rb Expression in Primary Superficial Bladder Cancer Journal of Urology. 155: 1784-1788. DOI: 10.1016/S0022-5347(01)66198-6 | 0.37 | |||
| 1996 | Goldenberg SL, Klotz LH, Srigley J, Jewett MA, Mador D, Fradet Y, Barkin J, Chin J, Paquin J, Bullock MJ, Laplante S. Randomized, Prospective, Controlled Study Comparing Radical Prostatectomy Alone and Neoadjuvant Androgen Withdrawal in the Treatment of Localized Prostate Cancer Journal of Urology. 156: 873-877. DOI: 10.1016/S0022-5347(01)65645-3 | 0.328 | |||
| 1995 | Shirai T, Fradet Y, Huland H, Bollack C, Droller M, Janknegt R, Jones P, Kagawa S. The etiology of bladder cancer--are there any new clues or predictors of behavior? International Journal of Urology : Official Journal of the Japanese Urological Association. 64-75. PMID 7553307 DOI: 10.1111/J.1442-2042.1995.Tb00481.X | 0.377 | |||
| 1995 | Fradet Y. Treatment of superficial bladder cancer Current Opinion in Urology. 5: 267-271. DOI: 10.1097/00042307-199509000-00011 | 0.385 | |||
| 1994 | Labrie F, Cusan L, Gomez J, Diamond P, Suburu R, Lemay M, Tetu B, Fradet Y, Candas B. Down-staging of early stage prostate cancer before radical prostatectomy: The first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist Urology. 44: 29-37. DOI: 10.1016/S0090-4295(94)80241-6 | 0.432 | |||
| 1993 | Rao JY, Hemstreet GP, Hurst RE, Bonner RB, Jones PL, Min KW, Fradet Y. Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America. 90: 8287-91. PMID 8367495 DOI: 10.1073/Pnas.90.17.8287 | 0.397 | |||
| 1993 | Dalbagni G, Reuter VE, Sheinfeld J, Fradet Y, Fair WR, Cordon-Cardo C. Cell surface differentiation antigens of normal urothelium and bladder tumors. Seminars in Surgical Oncology. 8: 293-9. PMID 1462100 DOI: 10.1002/Ssu.2980080508 | 0.385 | |||
| 1992 | Fradet Y, Friede J, Guertin B, Leclerc J, Dufour C, Caron C. Radioimmunodetection of human bladder tumor xenografts in nude mice with radiolabeled monoclonal antibodies. The Journal of Urology. 148: 418-22. PMID 1635152 DOI: 10.1016/S0022-5347(17)36620-X | 0.348 | |||
| 1992 | Hemstreet GP, Rao JY, Hurst RE, Bonner RB, Jones PL, Vaidya AM, Fradet Y, Moon RC, Kelloff GJ. Intermediate endpoint biomarkers for chemoprevention. Journal of Cellular Biochemistry. Supplement. 16: 93-110. PMID 1305696 DOI: 10.1002/Jcb.240501320 | 0.363 | |||
| 1992 | Fradet Y, Lafleur L, Larue H. Strategies of chemoprevention based on antigenic and molecular of early and premalignant lesions of the bladder Journal of Cellular Biochemistry. 50: 85-92. PMID 1305695 DOI: 10.1002/Jcb.240501319 | 0.357 | |||
| 1991 | Huland E, Huland H, Meier T, Baricordi O, Fradet Y, Grossman HB, Hodges GM, Messing EM, Schmitz-Draeger BJ. Comparison of 15 monoclonal antibodies against tumor-associated antigens of transitional cell carcinoma of the human bladder Journal of Urology. 146: 1631-1636. PMID 1719252 DOI: 10.1016/S0022-5347(17)38202-2 | 0.399 | |||
| 1990 | Fradet Y, LaRue H, Parent-Vaugeois C, Bergeron A, Dufour C, Boucher L, Bernier L. Monoclonal antibody against a tumor-associated sialoglycoprotein of superficial papillary bladder tumors and cervical condylomas. International Journal of Cancer. Journal International Du Cancer. 46: 990-7. PMID 1701166 DOI: 10.1002/Ijc.2910460607 | 0.344 | |||
| 1988 | Béland G, Elhilali M, Fradet Y, Laroche B, Ramsey EW, Trachtenberg J, Venner PM. Total androgen blockade for metastatic cancer of the prostate. American Journal of Clinical Oncology. 11: S187-90. PMID 3149456 DOI: 10.1097/00000421-198801102-00043 | 0.334 | |||
| 1987 | Fradet Y, Islam N, Boucher L, Parent-Vaugeois C, Tardif M. Polymorphic expression of a human superficial bladder tumor antigen defined by mouse monoclonal antibodies. Proceedings of the National Academy of Sciences of the United States of America. 84: 7227-31. PMID 3313389 DOI: 10.1073/Pnas.84.20.7227 | 0.353 | |||
| 1987 | Béland G, Elhilalli MM, Fradet Y, Laroche B, Ramsey EW, Trachtenberg J, Venner PN. Total androgen blockade for metastatic cancer of prostate European Journal of Cancer and Clinical Oncology. 23: 1233. DOI: 10.1016/0277-5379(87)90170-2 | 0.334 | |||
| Low-probability matches (unlikely to be authored by this person) | |||||
| 2017 | Vaughn DJ, Bellmunt J, Wit RD, Fradet Y, Lee J, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen WR, Gurney H, Quinn DI, Culine S, et al. Health-related quality of life (HRQoL) in the KEYNOTE-045 study of pembrolizumab versus investigator-choice chemotherapy for previously treated advanced urothelial cancer. Journal of Clinical Oncology. 35: 282-282. DOI: 10.1200/Jco.2017.35.6_Suppl.282 | 0.3 | |||
| 2006 | Fradet Y, Aprikian A, Dranitsaris G, Siemens R, Tsihlias J, Fleshner N. Does prolonging the time to bladder cancer surgery affect long-term cancer control: a systematic review of the literature. The Canadian Journal of Urology. 37-47. PMID 16818011 | 0.3 | |||
| 2009 | Shariat SF, Svatek RS, Skinner E, Karakiewicz PI, Capitanio U, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Novara G, Fritsche H, Müller SC, Izawa JI, Isbarn H, Stief CG, ... ... Fradet Y, et al. Lymphovascular Invasion Is A Powerful Predictor Of Clinical Outcomes In Node-Negative Radical Cystectomy Patients: An International External Validation Study The Journal of Urology. 181: 629-630. DOI: 10.1016/S0022-5347(09)61767-5 | 0.299 | |||
| 2010 | Lodde M, Lacombe L, Fradet Y. 621 PT2-3N0M0 PROSTATE CANCER WITH POSITIVE AND NEGATIVE MARGINS: CLINICAL OUTCOME AND TIME TO SALVAGE RADIOTHERAPY European Urology Supplements. 9: 207. DOI: 10.1016/S1569-9056(10)60610-0 | 0.298 | |||
| 1993 | Wheeless LL, Badalament RA, de Vere White RW, Fradet Y, Tribukait B. Consensus review of the clinical utility of DNA cytometry in bladder cancer. Report of the DNA Cytometry Consensus Conference. Cytometry. 14: 478-81. PMID 8354118 DOI: 10.1002/Cyto.990140504 | 0.298 | |||
| 2019 | Fradet Y. The treatment of prostate cancer: how is failure defined and how can it be minimized? The Canadian Journal of Urology. 4: 39-43. PMID 12735833 | 0.298 | |||
| 2007 | Fradet Y. Rebuttal: Should Canadians be offered systematic prostate cancer screening? YES. Canadian Family Physician Medecin De Famille Canadien. 53: 1140-3. PMID 17872801 | 0.297 | |||
| 2007 | Fradet Y. Should Canadians be offered systematic prostate cancer screening? Yes. Canadian Family Physician Medecin De Famille Canadien. 53: 989-92, 994-7. PMID 17872764 | 0.297 | |||
| 2010 | Nuhn P, Bastian PJ, Svatek RS, Karakiewicz PI, Skinner E, Fradet Y, Izawa JI, Kassouf W, Novara G, Montorsi F, Fritsche HM, Tilki D, Isbarn H, Ficarra V, Dinney CP, et al. 35 Concomitant Carcinoma In Situ Is Not Associated With Clinical Outcomes After Radical Cystectomy European Urology Supplements. 9: 45. DOI: 10.1016/S1569-9056(10)60043-7 | 0.297 | |||
| 2009 | Shariat SF, Bolenz C, Ashfaq R, Karakiewicz PI, Fradet Y, Isbarn H, Jeldres C, Rigaud J, Sagalowsky AI, Lotan Y. Predictive Value Of The Combination Of Immunohistochemical Markers In Patients With Pt1 Disease At Radical Cystectomy The Journal of Urology. 181: 373-374. DOI: 10.1016/S0022-5347(09)61056-9 | 0.297 | |||
| 2017 | Allaire J, Léger C, Ben-Zvi T, Nguilé-Makao M, Fradet Y, Lacombe L, Fradet V. Prospective Evaluation of Nutritional Factors to Predict the Risk of Complications for Patients Undergoing Radical Cystectomy: A Cohort Study. Nutrition and Cancer. 1-9. PMID 29083243 DOI: 10.1080/01635581.2017.1367941 | 0.296 | |||
| 2008 | Shariat S, Lotan Y, Karakiewicz P, Fradet Y, Ashfaq R, Stein J, Bastian P, Larue H, Nielsen M, Suardi N, Montorsi F, Groshen S, Müller S, Palapattu G, Karam J, et al. Multi-Institutional Evaluation Of The Predictive Value Of P53 Immunohistochemical Staining In Patients With Pt1-2 N0 Disease At Radical Cystectomy European Urology Supplements. 7: 78. DOI: 10.1016/S1569-9056(08)60033-0 | 0.295 | |||
| 2022 | Lacombe L, Hovington H, Brisson H, Mehdi S, Beillevaire D, Émond JP, Wagner A, Villeneuve L, Simonyan D, Ouellet V, Barrès V, Latour M, Aprikian A, Bergeron A, Castonguay V, ... ... Fradet Y, et al. UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways. Cancer Letters. 215994. PMID 36343786 DOI: 10.1016/j.canlet.2022.215994 | 0.294 | |||
| 2006 | Fradet Y, Picard V, Bergeron A, LaRue H. Cancer-testis antigen expression in bladder cancer. Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie. 15: 1303-13. PMID 16734221 | 0.293 | |||
| 2007 | Picard V, Bergeron A, Larue H, Fradet Y. MAGE-A9 mRNA and protein expression in bladder cancer. International Journal of Cancer. 120: 2170-7. PMID 17290406 DOI: 10.1002/Ijc.22282 | 0.293 | |||
| 2011 | Ayari C, Bergeron A, LaRue H, Ménard C, Fradet Y. Toll-like receptors in normal and malignant human bladders. The Journal of Urology. 185: 1915-21. PMID 21421234 DOI: 10.1016/J.Juro.2010.12.097 | 0.29 | |||
| 2021 | Kourbanhoussen K, Joncas FH, D Wallis CJ, Hovington H, Dagenais F, Fradet Y, Guillemette C, Lacombe L, Toren P. Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer. Asian Journal of Andrology. PMID 34259197 DOI: 10.4103/aja.aja_58_21 | 0.29 | |||
| 2008 | Sagalowsky A, Shariat S, Karakiewicz P, Fradet Y, Ashfaq R, Stein J, Bastian P, Nielsen M, Suardi N, Montorsi F, Groshen S, Mueller S, Rigaud J, Heukamp L, Netto G, et al. POD-7.09: Combination of Cell Cycle Regulating Bio-markers Improves Prognosis in Patients with Organ Confined Urothelial Cancer at Radical Cystectomy Urology. 72: S57. DOI: 10.1016/j.urology.2008.08.162 | 0.29 | |||
| 2000 | LaRue H, Allard P, Simoneau M, Normand C, Pfister C, Moore L, Meyer F, Têtu B, Fradet Y. P53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers. Carcinogenesis. 21: 101-6. PMID 10607740 DOI: 10.1093/Carcin/21.1.101 | 0.289 | |||
| 2000 | Pfister C, Larue H, Moore L, Lacombe L, Veilleux C, Tetu B, Meyer F, Fradet Y. Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes. International Journal of Cancer. 89: 100-4. PMID 10719738 DOI: 10.1002/(Sici)1097-0215(20000120)89:1<100::Aid-Ijc16>3.0.Co;2-Q | 0.289 | |||
| 2012 | Mauermann J, Fradet V, Hovington H, Lacombe L, Dujardin T, Tiguert R, Fradet Y. 786 Impact of extent of positive margins on different outcome parameters in 1712 treatment-naïve patients after pT2-4 N0 radical prostatectomy European Urology Supplements. 11: e786-e786a. DOI: 10.1016/S1569-9056(12)60783-0 | 0.289 | |||
| 2020 | Gevariya N, Lachance G, Robitaille K, Joly Beauparlant C, Beaudoin L, Fournier E, Fradet Y, Droit A, Julien P, Marette A, Bergeron A, Fradet V. Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity. Molecular Cancer Research : McR. PMID 33262291 DOI: 10.1158/1541-7786.MCR-20-0316 | 0.288 | |||
| 2012 | Kapoor A, Dason S, Allard C, Matsumoto E, Rendon R, Bell D, Izawa J, Chin J, So A, Black P, Lattouf J, Saad F, Jacobsen N, Fairey A, Drachenberg D, ... ... Fradet Y, et al. 641 Management Of The Intravesical Ureter And Bladder Cuff During Radical Nephroureterectomy: Outcomes From The Canadian Upper Tract Collaboration The Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.720 | 0.287 | |||
| 2001 | Grossman HB, Schmitz-Dräger B, Fradet Y, Tribukait B. Use of markers in defining urothelial premalignant and malignant conditions. Scandinavian Journal of Urology and Nephrology. Supplementum. 94-104. PMID 11144908 DOI: 10.1080/003655900750169347 | 0.287 | |||
| 2003 | Klotz LH, Fradet Y. Controversies in the management of localized prostate cancer: consensus development by Canadian urologists. The Canadian Journal of Urology. 30-5. PMID 12121593 | 0.287 | |||
| 1996 | Battelli MG, Polito L, Bolognesi A, Lafleur L, Fradet Y, Stirpe F. Toxicity of ribosome-inactivating proteins-containing immunotoxins to a human bladder carcinoma cell line. International Journal of Cancer. 65: 485-90. PMID 8621232 DOI: 10.1002/(Sici)1097-0215(19960208)65:4<485::Aid-Ijc16>3.0.Co;2-9 | 0.286 | |||
| 2011 | Tilki D, Reich O, Karakiewicz P, Novara G, Kassouf W, Fradet Y, Ficarra V, Seitz M, Skinner E, Svatek R, Lotan Y, Sagalowsky A, Stief C, Shariat S. 1892 Pt2 Substaging In Urothelial Carcinoma Of The Bladder: Deep Muscle Invasion Is Associated With Worse Outcome The Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.2016 | 0.285 | |||
| 2004 | Inman BA, Lacombe L, Fradet Y. 56: Utility of Routine Urine Cytology in the Followup of Patients with Studer Orthotopic Neobladders The Journal of Urology. 171: 15-15. DOI: 10.1016/S0022-5347(18)37318-X | 0.284 | |||
| 2003 | Aboulkassim TO, LaRue H, Lemieux P, Rousseau F, Fradet Y. Alteration of the PATCHED locus in superficial bladder cancer Oncogene. 22: 2967-2971. PMID 12771948 DOI: 10.1038/Sj.Onc.1206513 | 0.284 | |||
| 2010 | Shariat SF, Dinney CP, Lee R, Novara G, Fradet Y, Bastian P, Kassouf W, Karakiewicz PI, Fritsche H, Müller SC, Izawa JI, Lotan Y, Skinner E, Stief CG, Ficarra V, et al. Influence of Gender on Outcome following Radical Cystectomy: A Competing Risk Analysis Journal of Men's Health. 7. DOI: 10.1016/J.Jomh.2010.09.194 | 0.284 | |||
| 2007 | Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I, Fradet Y, Lacombe L, Kwon ED. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer. 109: 1499-505. PMID 17340590 DOI: 10.1016/S0022-5347(18)31107-8 | 0.284 | |||
| 2021 | Diop MK, Albadine R, Kougioumoutzakis A, Delvoye N, Hovington H, Bergeron A, Fradet Y, Saad F, Trudel D. Identification of Morphologic Criteria Associated with Biochemical Recurrence in Intraductal Carcinoma of the Prostate. Cancers. 13. PMID 34944863 DOI: 10.3390/cancers13246243 | 0.282 | |||
| 2017 | De Wit R, Bajorin DF, Bellmunt J, Fradet Y, Lee J, Fong L, Vogelzang NJ, Climent MÁ, Petrylak DP, Choueiri TK, Necchi A, Gerritsen WR, Gurney H, Quinn DI, Culine S, et al. Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE-045. Journal of Clinical Oncology. 35: 4530-4530. DOI: 10.1200/Jco.2017.35.15_Suppl.4530 | 0.282 | |||
| 2003 | Rigaud J, Tiguert R, Fradet Y. [Molecular markers of infiltrating cancer of the bladder]. Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie. 12: 1057-83. PMID 12536929 | 0.282 | |||
| 2007 | Fradet Y. MP-08.01: Salvage therapy with bicalutamide 150 mg in patients with PSA failure under LHRH therapy or surgical castration for advanced prostate cancer Urology. 70: 77. DOI: 10.1016/j.urology.2007.06.305 | 0.281 | |||
| 1991 | Wheeless LL, Reeder JE, O'Connell MJ, Robinson RD, Cosgriff JM, Fradet Y, Frank IN, Cockett AT. DNA slit-scan flow cytometry of bladder irrigation specimens and the importance of recognizing urothelial cells. Cytometry. 12: 140-6. PMID 2049971 DOI: 10.1002/Cyto.990120207 | 0.28 | |||
| 2020 | Vittrant B, Bergeron A, Molina OE, Leclercq M, Légaré XP, Hovington H, Picard V, Martin-Magniette ML, Livingstone J, Boutros PC, Collins C, Fradet Y, Droit A. Immune-focused multi-omics analysis of prostate cancer: leukocyte Ig-Like receptors are associated with disease progression. Oncoimmunology. 9: 1851950. PMID 33299664 DOI: 10.1080/2162402X.2020.1851950 | 0.28 | |||
| 2017 | Fraser M, Sabelnykova VY, Yamaguchi TN, Heisler LE, Livingstone J, Huang V, Shiah YJ, Yousif F, Lin X, Masella AP, Fox NS, Xie M, Prokopec SD, Berlin A, Lalonde E, ... ... Fradet Y, et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature. PMID 28068672 DOI: 10.1038/Nature20788 | 0.279 | |||
| 2013 | Saad F, Shore ND, Van Poppel H, Rathkopf D, Smith MR, de Bono JS, Logothetis C, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, et al. 713 ABIRATERONE ACETATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITHOUT PRIOR CHEMOTHERAPY - INTERIM ANALYSIS OF THE COU-AA-302 PHASE 3 TRIAL Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.272 | 0.278 | |||
| 2011 | Fradet V, Neveu B, Morel X, Julien P, Bergeron A, Larue H, Fradet Y. UP-02.229 Anti-Inflammatory Effects of Fish Oil (Omega-3 Fatty Acids) on Normal Human Prostate Epithelium Urology. 78: S340-S341. DOI: 10.1016/J.Urology.2011.07.1047 | 0.278 | |||
| 2019 | Fradet Y, Lockhard C. Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark. The Canadian Journal of Urology. 4: 400-405. PMID 12735818 | 0.277 | |||
| 2011 | Yafi F, Tanguay S, Rendon R, Jacobsen N, Fairey A, Izawa J, Kapoor A, Black P, Lacombe L, Chin J, So A, Lattouf J, Bell D, Fradet Y, Saad F, et al. UP-03.117 Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma Treated with Nephroureterectomy: Assessment of Adequate Renal Function and Impact on Outcome Urology. 78: S381-S382. DOI: 10.1016/J.Urology.2011.07.1206 | 0.275 | |||
| 2015 | Laverdière I, Flageole C, Audet-Walsh É, Caron P, Fradet Y, Lacombe L, Lévesque É, Guillemette C. The UGT1 locus is a determinant of prostate cancer recurrence after prostatectomy. Endocrine-Related Cancer. 22: 77-85. PMID 25452636 DOI: 10.1530/ERC-14-0423 | 0.275 | |||
| 2009 | Svatek RS, Shariat SF, Dinney CP, Novara G, Fradet Y, Bastian PJ, Kassouf W, Karakiewicz PI, Fritsche H, Muller SC, Izawa JI, Skinner E, Stief CG, Ficarra V, Volkmer BG, et al. EVIDENCE-BASED GENDER RELATED OUTCOMES AFTER RADICAL CYSTECTOMY: RESULTS OF A LARGE MULTICENTER STUDY The Journal of Urology. 181: 629. DOI: 10.1016/S0022-5347(09)61766-3 | 0.275 | |||
| 2022 | Berrehail Z, Boibessot C, Gris T, Joncas FH, Gaignier F, Guillemette C, Lacombe L, Fradet Y, Toren P. Sex steroid modulation of macrophages within the prostate tumor microenvironment. American Journal of Clinical and Experimental Urology. 10: 98-110. PMID 35528461 | 0.274 | |||
| 2007 | Fradet Y, Egerdie B, Andersen M, Tammela TL, Nachabe M, Armstrong J, Morris T, Navani S. Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study. European Urology. 52: 106-14. PMID 17270340 DOI: 10.1016/J.Eururo.2007.01.031 | 0.274 | |||
| 2010 | Stenzl A, Burger M, Fradet Y, Mynderse LA, Soloway MS, Witjes JA, Kriegmair M, Karl A, Shen Y, Grossman HB. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. The Journal of Urology. 184: 1907-13. PMID 20850152 DOI: 10.1016/j.juro.2010.06.148 | 0.274 | |||
| 2002 | Grégoire M, Liandier F, Naud A, Lacombe L, Fradet Y. Does the Potassium Stimulation Test Predict Cystometric, Cystoscopic Outcome in Interstitial Cystitis? Journal of Urology. 168: 556-557. DOI: 10.1016/S0022-5347(05)64678-2 | 0.273 | |||
| 2009 | Svatek RS, Shariat SF, Kassouf W, Novara G, Fradet Y, Bastian PJ, Karakiewicz PI, Fritsche H, Muller SC, Izawa JI, Dinney CP, Stief CG, Ficarra V, Kamat A, Volkmer BG, et al. PROGNOSTIC VALUE OF LYMPH NODE DENSITY IN A MULTI-CENTER, INTERNATIONAL COHORT OF PATIENTS WITH NODE POSITIVE UROTHELIAL CARCINOMA OF THE BLADDER Journal of Urology. 181: 125-125. DOI: 10.1016/S0022-5347(09)60358-X | 0.27 | |||
| 2011 | Yafi FA, Aprikian AG, Chin JL, Fradet Y, Izawa J, Estey E, Fairey A, Rendon R, Cagiannos I, Lacombe L, Lattouf JB, Bell D, Drachenberg D, Kassouf W. Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. Bju International. 108: 539-45. PMID 21166753 DOI: 10.1111/j.1464-410X.2010.09912.x | 0.269 | |||
| 2004 | Gomella LG, Grossman HB, Presti JC, Lerner SP, Cookson MS, Albala DM, Nseyo UO, Fradet Y, Bihrle R, Fuchs GJ, Morales A, Ritenour CWM, Droller MJ, Cure P. 264: The Use of Hexvix and Fluorescence Cystoscopy as an Adjunct in the Diagnosis of Carcinoma in Situ of the Urinary Bladder The Journal of Urology. 171: 69-70. DOI: 10.1016/S0022-5347(18)37526-8 | 0.269 | |||
| 1998 | Allard P, Bernard P, Fradet Y, Têtu B. The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. British Journal of Urology. 81: 692-8. PMID 9634043 DOI: 10.1046/j.1464-410x.1998.00628.x | 0.267 | |||
| 1999 | Simoneau M, Aboulkassim TO, LaRue H, Rousseau F, Fradet Y. Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31. Oncogene. 18: 157-63. PMID 9926930 DOI: 10.1038/Sj.Onc.1202277 | 0.266 | |||
| 2003 | Inman BA, Harel F, Tiguert R, Lacombe L, Fradet Y. Routine nasogastric tubes are not required following cystectomy with urinary diversion: a comparative analysis of 430 patients. The Journal of Urology. 170: 1888-91. PMID 14532800 DOI: 10.1097/01.Ju.0000092500.68655.48 | 0.265 | |||
| 1993 | Chabanas A, Rambeaud JJ, Seigneurin D, Fradet Y, Lawrence JJ, Faure G. Flow and image cytometry for DNA analysis in bladder washings: improved concordance by using internal reference for flow. Cytometry. 14: 943-50. PMID 8287737 DOI: 10.1002/Cyto.990140814 | 0.265 | |||
| 2017 | Allaire J, Ben-Zvi T, Lamarche B, Robitaille K, Fradet Y, Lacombe L, Fradet V. Preoperative nutritional factors and outcomes after radical cystectomy: A narrative review. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 29106362 DOI: 10.5489/Cuaj.4471 | 0.265 | |||
| 2013 | Bouchard F, Rimac G, Blouin A, Lefebvre V, Têtu B, Hovington H, Lemay C, Fradet V, Lacombe L, Fradet Y, Dujardin T, Tiguert R, Pouliot F. 2199 GLUT-1, GLUT-12 AND HK2 PROTEIN EXPRESSION IN PROSTATIC ADENOCARNINOMA: CLINICAL CORRELATION WITH INTRAPROSTATIC 18F-FDG-POSITRON EMISSION TOMOGRAPHY (FDG-PET) UPTAKE Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2108 | 0.264 | |||
| 2015 | Schmitz-Dräger BJ, Droller M, Lokeshwar VB, Lotan Y, Hudson MA, van Rhijn BW, Marberger MJ, Fradet Y, Hemstreet GP, Malmstrom PU, Ogawa O, Karakiewicz PI, Shariat SF. Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. Urologia Internationalis. 94: 1-24. PMID 25501325 DOI: 10.1159/000369357 | 0.263 | |||
| 2009 | Shariat S, Bolenz C, Karakiewicz P, Fradet Y, Bastian P, Ashfaq R, Groshen S, Nielsen M, Rigaud J, Mueller S, Heukamp L, Netto G, Lerner S, Sagalowsky A, Cote R, et al. 542 IMPROVED PREDICTION OF CLINICAL OUTCOMES IN PATIENTS WITH ADVANCED BLADDER CANCER USING A PANEL OF FOUR CELL CYCLE REGULATORS European Urology Supplements. 8: 256. DOI: 10.1016/S1569-9056(09)60538-8 | 0.263 | |||
| 2023 | Molina OE, LaRue H, Simonyan D, Hovington H, Têtu B, Fradet V, Lacombe L, Toren P, Bergeron A, Fradet Y. High infiltration of CD209 dendritic cells and CD163 macrophages in the peritumor area of prostate cancer is predictive of late adverse outcomes. Frontiers in Immunology. 14: 1205266. PMID 37435060 DOI: 10.3389/fimmu.2023.1205266 | 0.262 | |||
| 1997 | Bergeron A, LaRue H, Fradet Y. Biochemical analysis of a bladder-cancer-associated mucin: structural features and epitope characterization. The Biochemical Journal. 889-95. PMID 9032480 DOI: 10.1042/Bj3210889 | 0.262 | |||
| 1993 | Bonner RB, Hemstreet GP, Fradet Y, Rao JY, Min KW, Hurst RE. Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cells. Cancer. 72: 2461-9. PMID 8402463 DOI: 10.1002/1097-0142(19931015)72:8<2461::AID-CNCR2820720826>3.0.CO;2-C | 0.261 | |||
| 2010 | Chalasani V, Kassouf W, Izawa J, Fradet Y, Aprikian A, Fairey A, Estey E, Lacombe L, Rendon R, Bell D, Cagiannos I, Drachenberg D, Lattouf J, Chin J. 1028 IS PROSTATE-SPARING DURING RADICAL CYSTECTOMY ADVISABLE? Journal of Urology. 183. DOI: 10.1016/j.juro.2010.02.2063 | 0.261 | |||
| 2009 | Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U, Montorsi F, Bastian PJ, Nielsen ME, Müller SC, Rigaud J, Heukamp L, Netto GJ, Lerner SP, Sagalowsky AI, et al. MULTI-INSTITUTIONAL VALIDATION OF THE PREDICTIVE VALUE OF KI-67 LABELING INDEX IN PATIENTS WITH URINARY BLADDER CANCER Journal of Urology. 181: 69-69. DOI: 10.1016/S0022-5347(09)60201-9 | 0.261 | |||
| 2017 | Allaire J, Ben-Zvi T, Lamarche B, Robitaille K, Fradet Y, Lacombe L, Fradet V. Supplementary data: Preoperative nutritional factors and outcomes after radical cystectomy: A narrative review Canadian Urological Association Journal. 11: E465-8. DOI: 10.5489/Cuaj.5102 | 0.261 | |||
| 2005 | Tiguert R, Lacombe L, Fradet Y. Chapter 20 – Transurethral Surgery of Bladder Tumors Urologic Oncology-Seminars and Original Investigations. 358-367. DOI: 10.1016/B978-0-7216-0003-1.50023-X | 0.26 | |||
| 2012 | Auprich M, Haese A, Taille ADL, Van PH, Marberger M, Mulders PFA, Abbou CC, Stillebroer AB, Van GPMQ, Schalken JA, Stenzl A, Fradet Y, Marks LS, Ellis W, Partin AW, et al. 263 Development of novel PCA3 cut-offs for initial and repeat biopsy using different statistical approaches within a US-European multi institutional cohort European Urology Supplements. 11. DOI: 10.1016/S1569-9056(12)60260-7 | 0.26 | |||
| 2003 | LaRue H, Simoneau M, Aboulkassim TO, Lemieux P, Girard J, Hamed S, Hovington H, Jeannotte L, Fradet Y. La voie de signalisation PATCHED/Sonic Hedgehog dans le cancer superficiel de la vessie M S-Medecine Sciences. 19: 920-925. PMID 14613000 DOI: 10.1051/Medsci/20031910920 | 0.258 | |||
| 1991 | Wheeless LL, Coon JS, Cox C, Deitch AD, deVere White RW, Fradet Y, Koss LG, Melamed MR, O'Connell MJ, Reeder JE. Precision of DNA flow cytometry in inter-institutional analyses. Cytometry. 12: 405-12. PMID 1935456 DOI: 10.1002/Cyto.990120505 | 0.258 | |||
| 2016 | Kassouf W, Aprikian A, Black P, Kulkarni G, Izawa J, Eapen L, Fairey A, So A, North S, Rendon R, Sridhar SS, Alam T, Brimo F, Blais N, Booth C, ... ... Fradet Y, et al. Recommendations for the improvement of bladder cancer quality of care in canada: A consensus document reviewed and endorsed by bladder cancer canada (BCC), canadian urologic oncology group (CUOG), and canadian urological association (CUA), december 2015 Journal of the Canadian Urological Association. 10: E46-E80. DOI: 10.5489/cuaj.3583 | 0.257 | |||
| 1999 | Simoneau M, LaRue H, Fradet Y. Low frequency of human papillomavirus infection in initial papillary bladder tumors. Urological Research. 27: 180-4. PMID 10422819 DOI: 10.1007/S002400050107 | 0.254 | |||
| 2016 | Belledant A, Hovington H, Garcia L, Caron P, Brisson H, Villeneuve L, Simonyan D, Têtu B, Fradet Y, Lacombe L, Guillemette C, Lévesque E. The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression. European Urology. 69: 601-9. PMID 26215610 DOI: 10.1016/j.eururo.2015.06.054 | 0.252 | |||
| 2020 | Vittrant B, Leclercq M, Martin-Magniette ML, Collins C, Bergeron A, Fradet Y, Droit A. Identification of a Transcriptomic Prognostic Signature by Machine Learning Using a Combination of Small Cohorts of Prostate Cancer. Frontiers in Genetics. 11: 550894. PMID 33324443 DOI: 10.3389/fgene.2020.550894 | 0.252 | |||
| 2009 | Stenzl A, Roessler W, Fradet Y, Mynderse L, Soloway M, Kriegmair M, Witjes F, Grossman H. 1010 HEXVIX® FLUORESCENCE CYSTOSCOPY IMPROVES DETECTION AND RESECTION OF PAPILLARY BLADDER CANCER AND REDUCES EARLY RECURRENCE: A MULTICENTRE, PROSPECTIVE, RANDOMIZED STUDY European Urology Supplements. 8: 373. DOI: 10.1016/S1569-9056(09)60995-7 | 0.25 | |||
| 2022 | Boibessot C, Molina O, Lachance G, Tav C, Champagne A, Neveu B, Pelletier JF, Pouliot F, Fradet V, Bilodeau S, Fradet Y, Bergeron A, Toren P. Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype. Clinical and Translational Medicine. 12: e581. PMID 35075795 DOI: 10.1002/ctm2.581 | 0.25 | |||
| 2003 | Tiguert R, Inman IB, Têtu BT, Naud A, Grégoire M, Lacombe L, Fradet Y. Diagnosis and monitoring of bladder tumours using immunoCyt/uCyt+ in routine clinical practiced monitoring European Urology Supplements. 2: 193. DOI: 10.1016/S1569-9056(03)80763-7 | 0.25 | |||
| 2008 | Fradet Y, Lodde M, Levesque J, Harel F, Lacombe L, Dujardin T. POD-4.10: Phase II Study of Treatment with 5-Alpha Reductase Inhibitors (5ARIs) in Low-Risk Prostate Cancer Urology. 72: S43. DOI: 10.1016/j.urology.2008.08.086 | 0.249 | |||
| 2009 | Grossman HB, Mynderse L, Stenzl A, Burger M, Fradet Y, Soloway M, Zaak D, Kriegmair M, Witjes A. POD-07.01: Hexaminolevulinate New Data: Results from the Recurrence Study Urology. 74. DOI: 10.1016/J.Urology.2009.07.1140 | 0.247 | |||
| 2019 | Leclercq M, Vittrant B, Martin-Magniette ML, Scott Boyer MP, Perin O, Bergeron A, Fradet Y, Droit A. Large-Scale Automatic Feature Selection for Biomarker Discovery in High-Dimensional OMICs Data. Frontiers in Genetics. 10: 452. PMID 31156708 DOI: 10.3389/Fgene.2019.00452 | 0.247 | |||
| 2022 | Frégeau-Proulx L, Lacouture A, Berthiaume L, Weidmann C, Harvey M, Gonthier K, Pelletier JF, Neveu B, Jobin C, Bastien D, Bergeron A, Fradet Y, Lacombe L, Laverdière I, Atallah C, et al. Multiple metabolic pathways fuel the truncated tricarboxylic acid cycle of the prostate to sustain constant citrate production and secretion. Molecular Metabolism. 62: 101516. PMID 35598879 DOI: 10.1016/j.molmet.2022.101516 | 0.246 | |||
| 2007 | Groskopf J, Blase A, Koo S, Deras I, Aubin S, Rittenhouse H, Marks L, Fradet Y. 102 THE PCA3 SCORE IS INDEPENDENT OF PROSTATE GLAND VOLUME, AND CAN SYNERGIZE WITH OTHER PATIENT INFORMATION FOR PREDICTING BIOPSY OUTCOME European Urology Supplements. 6: 48. DOI: 10.1016/S1569-9056(07)60101-8 | 0.241 | |||
| 1990 | Béland G, Elhilali M, Fradet Y, Laroche B, Ramsey EW, Trachtenberg J, Venner PM, Tewari HD. A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma. Cancer. 66: 1074-9. PMID 2203517 DOI: 10.1002/cncr.1990.66.s5.1074 | 0.235 | |||
| 2003 | Klotz LH, Goldenberg SL, Jewett MA, Fradet Y, Nam R, Barkin J, Chin J, Chatterjee S. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. The Journal of Urology. 170: 791-4. PMID 12913699 DOI: 10.1097/01.JU.0000081404.98273.FD | 0.233 | |||
| 2016 | Jain P, Neveu B, Velot L, Wu L, Fradet Y, Pouliot F. Corrigendum: Bioluminescence Microscopy as a Method to Measure Single Cell Androgen Receptor Activity Heterogeneous Responses to Antiandrogens. Scientific Reports. 6: 37381. PMID 27869232 DOI: 10.1038/Srep37381 | 0.233 | |||
| 2004 | Inman BA, Lacombe L, Fradet Y. 50: Bacteriologic Profile of Studer Orthotopic Neobladders and the Risk of Urinary Tract Infection The Journal of Urology. 171: 14-14. DOI: 10.1016/S0022-5347(18)37312-9 | 0.233 | |||
| 2013 | Gomella L, Grossman HB, Droller M, Schmidbauer J, Hermann G, Dragoescu O, Ray E, Witjes A, Karl A, Stenzl A, Fradet Y, Burgues J, Jocham D. 1293 A META-ANALYSIS OF BLUE LIGHT CYSTOSCOPY WITH HEXAMINOLEVULINATE IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER Journal of Urology. 189. DOI: 10.1016/j.juro.2013.02.2647 | 0.232 | |||
| 2013 | Burger M, Grossman HB, Droller M, Schmidbauer J, Hermann G, Drăgoescu O, Ray E, Fradet Y, Karl A, Burgués JP, Witjes JA, Stenzl A, Jichlinski P, Jocham D. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. European Urology. 64: 846-54. PMID 23602406 DOI: 10.1016/j.eururo.2013.03.059 | 0.231 | |||
| 2023 | Gonthier K, Weidmann C, Berthiaume L, Jobin C, Lacouture A, Lafront C, Harvey M, Neveu B, Loehr J, Bergeron A, Fradet Y, Lacombe L, Riopel J, Latulippe É, Atallah C, et al. Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic-mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer. Molecular Oncology. PMID 37086156 DOI: 10.1002/1878-0261.13441 | 0.23 | |||
| 2023 | Savard J, Moussa H, Pelletier JF, Julien P, Lacombe L, Tiguert R, Caumartin Y, Dujardin T, Toren P, Pouliot F, Lodde M, Fradet Y, Robitaille K, Fradet V. Effects of omega-3 supplementation on psychological symptoms in men with prostate cancer: Secondary analysis of a double-blind placebo-controlled randomized trial. Cancer Medicine. 12: 20163-20176. PMID 37787025 DOI: 10.1002/cam4.6598 | 0.228 | |||
| 2000 | NAM RK, REDELMEIER DA, SPIESS PE, SAMPSON HA, FRADET Y, JEWETT MA. COMPARISON OF MOLECULAR AND CONVENTIONAL STRATEGIES FOR FOLLOWUP OF SUPERFICIAL BLADDER CANCER USING DECISION ANALYSIS Journal of Urology. 163: 752-757. DOI: 10.1016/S0022-5347(05)67797-X | 0.227 | |||
| 2023 | Garneau CA, Marcotte N, Lacombe L, Fradet Y, Fradet V, Pouliot F, Toren P, Lodde M. Salvage therapy for BCG failure with intravesical sequential gemcitabine and docetaxel in patients with recurrent NMIBC. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 37931285 DOI: 10.5489/cuaj.8341 | 0.225 | |||
| 2009 | Groskopf J, Siddiqui J, Aubin SMJ, Sefton-Miller L, Day J, Blase A, Varambally S, Schalken J, Sakamoto K, Fradet Y, Rittenhouse H, Chinnaiyan A. 297 Feasibility And Clinical Utility Of A Tmprss2:Erg Gene Fusion Urine Test European Urology Supplements. 8: 195. DOI: 10.1016/S1569-9056(09)60302-X | 0.224 | |||
| 2010 | De Serres SA, Caumartin Y, Noël R, Lachance JG, Côté I, Naud A, Fradet Y, Mfarrej BG, Agharazii M, Houde I. Dual-kidney transplants as an alternative for very marginal donors: long-term follow-up in 63 patients. Transplantation. 90: 1125-30. PMID 20921934 DOI: 10.1097/Tp.0B013E3181F8F2B8 | 0.224 | |||
| 2009 | Lodde M, Saourine A, Lacombe L, Dujardin T, Morin F, Friede J, Fradet Y. EVALUATION OF FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY ASSOCIATED WITH COMPUTED TOMOGRAPHY ( 18 F-FDG-PET/CT)IMAGING FOR STAGING OF BLADDER TRANSITIONAL CELL CARCINOMA Journal of Urology. 181: 376-376. DOI: 10.1016/S0022-5347(09)61062-4 | 0.22 | |||
| 2022 | Bellmunt J, de Wit R, Fradet Y, Climent MA, Petrylak DP, Lee JL, Fong L, Necchi A, Sternberg CN, O'Donnell PH, Powles T, Plimack ER, Bajorin DF, Balar AV, Castellano D, et al. Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results From the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35247908 DOI: 10.1158/1078-0432.CCR-21-3089 | 0.216 | |||
| 2006 | Fradet Y, Egerdie, Andersen M, Tammela T, Nachabe M, Armstrong J, Morris T, Navani S. Mp-08.12 Urology. 68: 99-100. DOI: 10.1016/J.Urology.2006.08.319 | 0.213 | |||
| 1988 | Fradet Y, Lebel M, Grose JH, Talbot J, Charrois R. Renal prostaglandins in postobstructive diuresis. Comparative study of unilateral and bilateral obstruction in conscious dogs. Prostaglandins, Leukotrienes, and Essential Fatty Acids. 31: 123-9. PMID 3375286 DOI: 10.1016/0952-3278(88)90108-1 | 0.211 | |||
| 2003 | Fradet Y. Recent advances in the management of superficial bladder tumors. The Canadian Journal of Urology. 9: 1544-50. PMID 12121579 | 0.21 | |||
| 2010 | Lodde M, Lacombe L, Friede J, Morin F, Saourine A, Fradet Y. Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma. Bju International. 106: 658-63. PMID 20151968 DOI: 10.1111/J.1464-410X.2010.09212.X | 0.209 | |||
| 1997 | Lee E, Schwaibold H, Fradet Y, Huland E, Huland H. Tumor-Associated Antigens in Normal Mucosa of Patients With Superficial Transitional Cell Carcinoma of the Bladder Journal of Urology. 157: 1070-1073. DOI: 10.1016/S0022-5347(01)65143-7 | 0.204 | |||
| 2020 | Bilodeau JF, Gevariya N, Larose J, Robitaille K, Roy J, Oger C, Galano JM, Bergeron A, Durand T, Fradet Y, Julien P, Fradet V. Long chain omega-3 fatty acids and their oxidized metabolites are associated with reduced prostate tumor growth. Prostaglandins, Leukotrienes, and Essential Fatty Acids. 164: 102215. PMID 33276284 DOI: 10.1016/j.plefa.2020.102215 | 0.199 | |||
| 2022 | Fadel J, Simonyan D, Fradet V, Lodde M, Lacombe L, Fradet Y, Toren P. Analysis of sex-based differences to Bacillus Calmette-Guérin for non-muscle invasive bladder cancer. Urologic Oncology. PMID 36272848 DOI: 10.1016/j.urolonc.2022.09.024 | 0.197 | |||
| 2017 | Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. The New England Journal of Medicine. PMID 28212060 DOI: 10.1056/NEJMoa1613683 | 0.194 | |||
| 2021 | Fradet S, Pelletier JF, Singbo N, Lacombe L, Toren P, Lodde M, Dujardin T, Tiguert R, Fradet Y, Robitaille K, Fradet V. Effects of omega-3 fatty acids supplementation on perioperative blood loss and complications after radical prostatectomy. Clinical Nutrition Espen. 47: 221-226. PMID 35063205 DOI: 10.1016/j.clnesp.2021.12.011 | 0.193 | |||
| 2023 | Moussa H, Robitaille K, Pelletier JF, Tourigny R, Fradet Y, Lacombe L, Toren P, Lodde M, Tiguert R, Dujardin T, Caumartin Y, Duchesne T, Julien P, Savard J, Diorio C, et al. Effects of Concentrated Long-Chain Omega-3 Polyunsaturated Fatty Acid Supplementation on Quality of Life after Radical Prostatectomy: A Phase II Randomized Placebo-Controlled Trial (RCT-EPA). Nutrients. 15. PMID 36986098 DOI: 10.3390/nu15061369 | 0.192 | |||
| 2015 | Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, Skinner E, Denzinger S, Fradet Y, Isbarn H, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Tilki D, et al. Corrigendum to "Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort" [Eur Urol 2010;57:300-9] European Urology. DOI: 10.1016/j.eururo.2015.02.007 | 0.191 | |||
| 2010 | Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, Skinner E, Denzinger S, Fradet Y, Isbarn H, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Tilki D, et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. European Urology. 57: 300-9. PMID 19766384 DOI: 10.1016/j.eururo.2009.09.024 | 0.191 | |||
| 2023 | Diop MK, Molina OE, Birlea M, LaRue H, Hovington H, Têtu B, Lacombe L, Bergeron A, Fradet Y, Trudel D. Leukocytic Infiltration of Intraductal Carcinoma of the Prostate: An Exploratory Study. Cancers. 15. PMID 37190147 DOI: 10.3390/cancers15082217 | 0.187 | |||
| 1984 | Fradet Y, Cordon-Cardo C, Thomson T, Daly ME, Whitmore WF, Lloyd KO, Melamed MR, Old LJ. Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies. Proceedings of the National Academy of Sciences of the United States of America. 81: 224-8. PMID 6364135 DOI: 10.1073/Pnas.81.1.224 | 0.184 | |||
| 2000 | Hauck EW, Altinkilic BM, Ludwig M, Lüdecke G, Schroeder-Printzen I, Arens C, Weidner W, Schulman CC, Debruyne FMJ, Forster G, Selvaggi FP, Zlotta AR, Witjes WPJ, Sevinç M, Kırkalı Z, ... ... Fradet Y, et al. Acknowledgement to the Reviewers European Urology. 34: 528-529. DOI: 10.1159/000019796 | 0.184 | |||
| 2020 | Koti M, Berman DM, Siemens DR, Lange D, Wang E, Toren P, Eigl BJ, Hardy C, Purves R, Fradet V, Fradet Y, Mansure J, Kassouf W, Black PC. Building a Canadian Translational Bladder Cancer Research Network. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 14: E475-E481. PMID 33275556 DOI: 10.5489/cuaj.6887 | 0.18 | |||
| 2020 | Al-Hogbani M, Gilbert S, Lodde M, Fradet Y, Toren P. Does 5-alpha Reductase Inhibitor Use Improve The Efficacy of Intravesical Bacille Calmette-Guérin (BCG) for Non-muscle Invasive Bladder Cancer? Bladder Cancer. 6: 63-69. DOI: 10.3233/blc-190262 | 0.18 | |||
| 2019 | Lacombe L, Fradet Y. Blood management and radical retropubic prostatectomy: Quebec experience. The Canadian Journal of Urology. 6: 727-731. PMID 11178596 | 0.178 | |||
| 2000 | Hauck EW, Altinkilic BM, Ludwig M, Lüdecke G, Schroeder-Printzen I, Arens C, Weidner W, Schulman CC, Debruyne FMJ, Forster G, Selvaggi FP, Zlotta AR, Witjes WPJ, Sevinç M, Kırkalı Z, ... ... Fradet Y, et al. Contents Vol. 38, 2000 European Urology. 38: 789-794. DOI: 10.1159/000020384 | 0.177 | |||
| 2000 | Hauck EW, Altinkilic BM, Ludwig M, Lüdecke G, Schroeder-Printzen I, Arens C, Weidner W, Schulman CC, Debruyne FMJ, Forster G, Selvaggi FP, Zlotta AR, Witjes WPJ, Sevinç M, Kırkalı Z, ... ... Fradet Y, et al. Subject Index Vol. 38, 2000 European Urology. 38: 786-787. DOI: 10.1159/000020382 | 0.176 | |||
| 1999 | Ekman P, Fradet Y, Meyer F, Bairati I, Shadmani R, Moore L, Peehl DM, Moul JW, Klocker H, Culig Z, Eder IE, Nessler-Menardi C, Hobisch A, Putz T, Bartsch G, et al. Subject Index Vol. 35, 1999 European Urology. 35: 554-556. DOI: 10.1159/000019901 | 0.176 | |||
| 2006 | Lacombe L, Decobert M, Harel F, Larue H, Steinhoff G, Kinahan J, Fradet Y. PD-11.02 Urology. 68: 38. DOI: 10.1016/J.Urology.2006.08.121 | 0.175 | |||
| 2015 | Beauregard JM, Blouin AC, Fradet V, Caron A, Fradet Y, Lemay C, Lacombe L, Dujardin T, Tiguert R, Rimac G, Bouchard F, Pouliot F. FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy. Cancer Imaging : the Official Publication of the International Cancer Imaging Society. 15: 2. PMID 25889163 DOI: 10.1186/S40644-015-0038-0 | 0.172 | |||
| 1999 | Ekman P, Fradet Y, Meyer F, Bairati I, Shadmani R, Moore L, Peehl DM, Moul JW, Klocker H, Culig Z, Eder IE, Nessler-Menardi C, Hobisch A, Putz T, Bartsch G, et al. Vol. 35, 1999 European Urology. 35. DOI: 10.1159/000019903 | 0.169 | |||
| 1999 | Orlow I, LaRue H, Osman I, Lacombe L, Moore L, Rabbani F, Meyer F, Fradet Y, Cordon-Cardo C. Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. The American Journal of Pathology. 155: 105-13. PMID 10393843 DOI: 10.1016/S0002-9440(10)65105-X | 0.165 | |||
| 2004 | Trudel D, Fradet Y, Harel F, Meyer F, Têtu B. Corrélations entre la protéase MMP-2, l’activateur MT1-MMP et l’inhibiteur TIMP-2 dans le cancer de la prostate Annales De Pathologie. 24: 98. DOI: 10.1016/S0242-6498(04)93931-4 | 0.165 | |||
| 2015 | Paquet ÉR, Hovington H, Brisson H, Lacombe C, Larue H, Têtu B, Lacombe L, Fradet Y, Lebel M. Low level of the X-linked ribosomal protein S4 in human urothelial carcinomas is associated with a poor prognosis. Biomarkers in Medicine. 9: 187-97. PMID 25731206 DOI: 10.2217/bmm.14.115 | 0.16 | |||
| 1995 | Ravery V, Colombel M, Popov Z, Bastuji S, Patard JJ, Bellot J, Abbou CC, Fradet Y, Chopin DK. Prognostic value of epidermal growth factor-receptor, T138 and T43 expression in bladder cancer. British Journal of Cancer. 71: 196-200. PMID 7819039 DOI: 10.1038/bjc.1995.40 | 0.157 | |||
| 2014 | Klotz L, Drachenberg D, Singal R, Aprikian A, Fradet Y, Kebabdjian M, Zarenda M, Chin J. An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study. Prostate Cancer and Prostatic Diseases. 17: 320-4. PMID 25179591 DOI: 10.1038/pcan.2014.24 | 0.154 | |||
| 2009 | Shariat S, Bolenz C, Karakiewicz P, Fradet Y, Isbarn H, Jeldres C, Ashfaq R, Rigaud J, Sagalowsky A, Lotan Y. 671 PREDICTIVE VALUE OF THE COMBINATION OF IMMUNOSTOCHEMICAL MARKERS IN PATIENTS WITH PT1 DISEASE AT RADICAL CYSTECTOMY European Urology Supplements. 8: 288. DOI: 10.1016/S1569-9056(09)60666-7 | 0.153 | |||
| 1998 | Gleave ME, Elhilali M, Fradet Y, Davis I, Venner P, Saad F, Klotz LH, Moore MJ, Paton V, Bajamonde A. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. The New England Journal of Medicine. 338: 1265-71. PMID 9562580 DOI: 10.1056/NEJM199804303381804 | 0.148 | |||
| 2021 | Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. The Lancet. Oncology. PMID 34051178 DOI: 10.1016/S1470-2045(21)00152-2 | 0.144 | |||
| 2021 | Otis-Chapados S, Goulet CR, Dubois G, Lavallée É, Dujardin T, Fradet Y, Lacombe L, Lodde M, Tiguert R, Toren P, Fradet V, Beauregard JM, Buteau FA, Pouliot F. F-Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 33750523 DOI: 10.5489/cuaj.7107 | 0.141 | |||
| 2009 | Andreu N, Meyer F, Teuff GL, Lacombe L, Fradet Y, Tetu B. 7115 Prognostic value of cyclooxygenase-1 and cyclooxygenase-2 expressions in human renal cell carcinoma European Journal of Cancer Supplements. 7: 427. DOI: 10.1016/S1359-6349(09)71448-X | 0.126 | |||
| 1994 | Lévesque L, Douville P, Parent C, Fradet Y. Selection of monoclonal antibodies for the development of a simple urinary test for bladder tumor detection Clinical Biochemistry. 27: 200. DOI: 10.1016/0009-9120(94)90065-5 | 0.125 | |||
| 2024 | Robitaille K, Guertin MH, Jamshidi A, Xu HW, Hovington H, Pelletier JF, Beaudoin L, Gevariya N, Lacombe L, Tiguert R, Caumartin Y, Dujardin T, Toren P, Lodde M, Racine É, ... ... Fradet Y, et al. A phase IIb randomized placebo-controlled trial testing the effect of MAG-EPA long-chain omega-3 fatty acid dietary supplement on prostate cancer proliferation. Communications Medicine. 4: 56. PMID 38519581 DOI: 10.1038/s43856-024-00456-4 | 0.12 | |||
| 2013 | Alesawi A, Caron A, Bergeron A, Hovington H, Fradet V, Lacombe L, Fradet Y. 1297 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY FOR PREOPERATIVE STAGING AND POSTOPERATIVE FOLLOW-UP OF UROTHELIAL CARCINOMA Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2651 | 0.119 | |||
| 2021 | Lambert M, Benmoussa A, Diallo I, Ouellet-Boutin K, Dorval V, Majeau N, Joly-Beauparlant C, Droit A, Bergeron A, Têtu B, Fradet Y, Pouliot F, Provost P. Identification of Abundant and Functional dodecaRNAs (doRNAs) Derived from Ribosomal RNA. International Journal of Molecular Sciences. 22. PMID 34575920 DOI: 10.3390/ijms22189757 | 0.11 | |||
| 2022 | Turcotte B, Bélanger L, Blais AS, Blouin AC, Bolduc S, Bolduc-Mokhtar A, Bureau M, Caumartin Y, Cloutier J, Deschênes-Rompré MP, Dujardin T, Fradet Y, Gaudreau N, Lacombe L, Moore K, et al. Perception and satisfaction of patients after telemedicine urology consultations: A matched analysis with physicians' perspective. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 35621285 DOI: 10.5489/cuaj.7819 | 0.107 | |||
| 2012 | Bachir BG, Yafi FA, Aprikian A, Chin JL, Izawa J, Fradet Y, Lacombe L, Drachenberg D, Estey E, Fairey A, Rendon R, Bell D, Lattouf J, Cagiannos I, Kassouf W. 1762 REGIONAL DIFFERENCES IN PRACTICE PATTERNS AND OUTCOMES AFTER RADICAL CYSTECTOMY Journal of Urology. 187. DOI: 10.1016/j.juro.2012.02.1778 | 0.106 | |||
| 1984 | Cordon-Cardo C, Bander NH, Fradet Y, Finstad CL, Whitmore WF, Lloyd KO, Oettgen HF, Melamed MR, Old LJ. Immunoanatomic dissection of the human urinary tract by monoclonal antibodies. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 32: 1035-40. PMID 6384360 DOI: 10.1177/32.10.6384360 | 0.101 | |||
| 1994 | Ooi A, Herz F, Ii S, Cordoncardo C, Fradet Y, Mayall B. Ha-ras codon 12 mutation in papillary tumors of the urinary-bladder - a retrospective study. International Journal of Oncology. 4: 85-90. PMID 21566894 DOI: 10.3892/ijo.4.1.85 | 0.099 | |||
| 1999 | Gleave M, Elhilali M, Fradet Y, Davis I, Venner P, Saad F, Klotz L, Moore M, Paton V, Bajamonde A. Interferon Gamma-1b Compared With Placebo in Metastatic Renal-Cell Carcinoma Journal of Urology. 161: 1736-1737. DOI: 10.1016/S0022-5347(05)69051-9 | 0.098 | |||
| 2022 | Messaoudene M, Pidgeon R, Richard C, Ponce M, Diop K, Benlaifaoui M, Nolin-Lapalme A, Cauchois F, Malo J, Belkaid W, Isnard S, Fradet Y, Dridi L, Velin D, Oster P, et al. A natural polyphenol exerts antitumor activity and circumvents anti-PD-1 resistance through effects on the gut microbiota. Cancer Discovery. PMID 35031549 DOI: 10.1158/2159-8290.CD-21-0808 | 0.092 | |||
| 1981 | Roy R, Fradet Y, Lachance JG. Influence of HLA-A and HLA-B cross-reactive antigen matching on kidney graft survival. Tissue Antigens. 18: 101-4. PMID 7038984 DOI: 10.1111/J.1399-0039.1981.Tb01371.X | 0.09 | |||
| 1981 | Roy R, Lachance JG, Fradet Y, Hebert J. Characterization of lymphocytotoxic antibodies in renal transplantation. Transplantation. 31: 31-3. PMID 7015597 DOI: 10.1097/00007890-198101000-00008 | 0.075 | |||
| 2020 | Turcotte B, Paquet S, Blais AS, Blouin AC, Bolduc S, Bureau M, Caumartin Y, Cloutier J, Deschênes-Rompré MP, Dujardin T, Fradet Y, Lacombe L, Moore K, Morin F, Nadeau G, et al. A prospective, multisite study analyzing the percentage of urological cases that can be completely managed by telemedicine. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 14: 319-321. PMID 33275552 DOI: 10.5489/cuaj.6862 | 0.07 | |||
| 2012 | Fradet Y. Cost-effectiveness of fluorescent cystoscopy for noninvasive papillary tumors: pro. The Journal of Urology. 187: 1537-9. PMID 22425096 DOI: 10.1016/j.juro.2012.02.2563 | 0.069 | |||
| 2002 | Grégoire M, Liandier F, Naud A, Lacombe L, Fradet Y. Does the potassium stimulation test predict cystometric, cystoscopic outcome in interstitial cystitis? The Journal of Urology. 168: 556-7. PMID 12131308 | 0.063 | |||
| 1980 | Fradet Y, Simard J, Grose JH, Lebel M. Enhanced urinary prostaglandin E2 in postobstructive diuresis in humans. Prostaglandins and Medicine. 5: 29-30. PMID 7403337 DOI: 10.1016/0161-4630(80)90087-7 | 0.063 | |||
| 1975 | Tardieu M, Fradet Y, Daguillard F. Immunological activities of rat lymphocytes. II. Isolation of suppressor cells of the mitogenic response of rat thoracic duct lymphocytes. Cellular Immunology. 17: 123-30. PMID 47788 DOI: 10.1016/S0008-8749(75)80012-8 | 0.041 | |||
| 1977 | Fradet Y, Roy R, Daguillard F. Regulation of in vitro lymphocyte responses. I. Adjuvant effect of lipopolysaccharide (LPS) on low-zone unresponsiveness to concanavalin A. Cellular Immunology. 27: 94-101. PMID 791510 DOI: 10.1016/0008-8749(76)90157-X | 0.041 | |||
| 2004 | Pommerville P, Goldenberg SL, Wilson JW, Fradet Y, Corcos J, Morris BA. A survey of urological manpower, technology, and resources in Canada. The Canadian Journal of Urology. 11: 2290-5. PMID 15287996 | 0.026 | |||
| 2018 | Joseph JV, Brasacchio R, Fung C, Reeder J, Bylund K, Sahasrabudhe D, Yeh SY, Ghazi A, Fultz P, Rubens D, Wu G, Singer E, Schwarz E, Mohile S, Mohler J, ... ... Fradet Y, et al. A Festschrift in Honor of Edward M. Messing, MD, FACS. Bladder Cancer (Amsterdam, Netherlands). 4: S1-S43. PMID 30443561 DOI: 10.3233/BLC-189037 | 0.013 | |||
| Hide low-probability matches. | |||||